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Chapter 1 
1.1 BRONCHIAL HYPERRESPONSIVENESS: DEFINITION AND 
CLINICAL ASPECTS 
Asthma is a disease characterized by paroxysms of dyspnea, wheezing and/or 
cough in a varying degree from indetectible mild to very severe '. In asthma an increased 
responsiveness of the tracheobronchial tree to a variety of stimuli is a characteristic 
feature. This phenomenon of bronchial hyperresponsiveness can be defined as an 
exaggerated bronchoconstrictor response of the airways on exposure to a small quantity of 
non-specific stimuli which do not not provoke such a reaction in normal subjects \ In 
contrast to a specific, allergic stimulus, the bronchoconstrictor response in non-specific 
bronchial hyperresponsiveness is not related to one particular stimulus, but to a variety of 
stimuli 3·4. Bronchial hyperresponsiveness has become of main interest in the 
investigations of the underlying pathophysiological mechanisms and pharmacological 
treatment modalities in asthma w . Several studies have made clear that there seems to be 
a relation between the severity of bronchial hyperresponsiveness and the clinical prognosis 
of asthmatic subjects *•". The presence of bronchial hyperresponsiveness in childhood is a 
risk factor for the development of chronic obstructive pulmonary disease (COPD) in 
adulthood ^10·". Bronchial hyperresponsiveness in adult COPD patients is associated with 
an accelerated longitudinal decline in lung function 7'',". Therefore, the assessment of 
bronchial hyperresponsiveness and farmacological modulation is very important in the 
treatment of asthmatic patients. 
The non-specific stimuli that can cause bronchusobstruction in susceptible patients are 
presented in table 1. These stimuli are used in bronchoprovocation tests, to assess the 
relationship between a given dose of inhaled stimulus and the change in lung function 
caused by it. This relationship reflects the magnitude of bronchial hyperresponsiveness. 
Bronchial hyperresponsiveness can lead to respiratory symptoms like dyspnoea 
and wheezing. Also coughing without bronchoconstriction can occur as the sole effect of 
bronchial hyperresponsiveness '3. Variations in bronchoconstriction during day and night 
are a well-known phenomenon, especially late at night and early in the morning an 
increase in bronchoconstriction can be found 14. Ryan et al. 14 demonstrated that in 
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asthmatic patients there was a close relationship between diumal variation in peak 
expiratory flow rate and the PC^histamine, the concentration of inhaled histamine causing 
a 20% fall in FEV,. This threshold is used to measure the degree of bronchial 
hyperresponsiveness. In this study reversibility of bronchoconstnction caused by 
bronchodilator drugs also correlated with the histamine threshold M. Other investigators, 
however, could not reproduce these findings "•",. 
Table 1: Pharmacological, physical and chemical agents causing brondiusobstntction in asthmatic subjects. 
PHARMACOLOGICAL STIMULI: histamine M, methacholme M, acetylcholine \ carbachol *, 
propranolol n, leukotnenes 4 2 '4\ prostaglandins *", adenosine α, 
platelet-activating factor " , neurokinin A 47, bradykinin " , 
PHYSICAL STIMULI: exercise " , hyperventilation 32, cold air 33, fog \ distilled water " , 
hypertonic solutions M . 
CHEMICAL STIMULI: S0 2 * , ozone », citnc acid
 4
. 
Sleep-related symptoms are often seen in asthma and at the same time an increase 
in bronchial hyperresponsiveness has been established '7'". Martin et al. demonstrated an 
increased cellular inflammatory response in the bronchoalveolar lavage fluid during the 
night in patients with nocturnal asthma ". Also decreased plasma levels of adrenaline 
during the night and increased vagal tone have been suggested as cause of nocturnal 
bronchoconstnction ™. 
Subjective parameters derived from a questionnaire of pulmonary symptoms, 
however, showed a poor relationship with the objective parameters such as lung function 
and bronchial hyperresponsiveness to histamine and methacholine ^2 ' . In the diagnosis 
and treatment of bronchial asthma, therefore, assessments of bronchial 
hyperresponsiveness and lung function measurements are crucial. 
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1.2 ASSESSMENT OF BRONCHIAL HYPERRESPONSIVENESS 
Bronchial hyperresponsiveness is usually assessed with histamine or methacholine 
inhalation challenges u. Both histamine and methacholine provocation tests have been well 
standardized ^27 and therefore have been shown to be reproducible and sensitive tests in 
the diagnosis and assessment of disease severity in asthmatic subjects 27"2'. Since bronchial 
hyperresponsiveness is caused by a complex pathophysiologic process in the airway wall, 
a challenge test with histamine and methacholine presumably only detects certain 
components of the mechanisms underlying bronchial hyperresponsiveness. The histamine-
and methacholine-induced bronchoconstrictor response is mainly the result of a direct 
effect of these agents on the airway smooth muscles ". Physical stimuli, however, may 
assess a more complete pathway of bronchial hyperresponsiveness. Exposure to exercise 
and distilled water results in the release of mediators in the airway wall leading to airway 
smooth muscle contraction *. Pauwels et al. suggested the distinction of direct and 
indirect stimuli in bronchial hyperresponsiveness measurements, reflecting the direct or 
indirect effect of these stimuli on the airway smooth muscles *. 
An advantage of the physical, indirect agents is the similarity to naturally 
occurring non-specific stimuli in daily life, and therefore a probably better correlation 
with day-to-day symptoms in asthma has been suggested ^27. Another advantage of these 
physical stimuli is that the bronchoconstriction they induce is specific for asthma. Patients 
without asthma do not react to these stimuli3I3<, whereas they do react to pharmacological 
ones. For if an appropriate dose of inhaled histamine or methacholine is administered, 
normals react with bronchoconstriction ". 
The main purpose of this thesis is to determine whether in clinical studies on 
bronchial hyperresponsiveness in asthma, a physical stimulus like ultrasonically nebulized 
distilled water (UNDW) will have advantages over histamine inhalations. In contrast to 
exercise, bronchoprovocation with inhaled distilled water offers the opportunity of 
constructing a dose-response curve and calculating a threshold, i.e. PDJDUNDW as 
described in detail in chapter 4 34,M. This makes a good comparison with the 
PDJiistamine, the histamine threshold dose which may be concidered as the golden 
standard for bronchial responsiveness, possible. Another advantage of UNDW challenge 
16 
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is that the test is not limited by the locomotive system of the patient, in contrast to 
exercise testing. Furthermore, bronchoprovocation with UNDW only last a relatively 
short time, is well tollerated by the patients, and easy to perform 37J8. Therefore, we have 
choosen bronchoprovocation with UNDW as an indirect stimulus to investigate bronchial 
hyperresponsiveness in comparison with histamine. 
1.3 AIM OF THE STUDIES 
In this thesis several aspects of bronchial hyperresponsiveness to ultrasonically 
nebulized distilled water and histamine in asthmatic subjects, with respect to clinical 
investigations, are described. 
The aims of the investigations presented in this thesis are: 
1. To determine whether in clinical studies on bronchial hyperresponsiveness in 
asthma, a physical stimulus like ultrasonically nebulized distilled water will have 
advantages over a pharmacological stimulus like histamine. 
2. Validation of the histamine provocation test using a new dosimeter (Jaeger APS), 
to investigate the reproducibility of this test and to compare this technique with the 2-
minute tidal breathing technique, (chapter 2) 
3. To validate the method of UNDW provocation for the assessment of bronchial 
hyperresponsiveness in asthmatic subjects. To investigate several aspects of this method: 
the reproducibility of the test, the shape of the dose-response curves, the duration of the 
distilled water-induced bronchoconstrictor effect and its relationship with the histamine-
induced bronchoconstriction in asthmatic subjects (chapter 4). 
4. To investigate the interaction of subsequent histamine and UNDW provocation 
tests and whether inhalation of histamine before UNDW-induced and histamine-induced 
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bronchoconstriction can cause refractoriness for one or both of these stimuli (chapter 5). 
5. To compare the protective effect of the inhaled muscarine receptor antagonist 
ipratropium bromide on the UNDW-induced bronchoconstrictor response with the ß2-
agonist terbutaline. (chapter 6). 
6. To compare the effects of long-term treatment with the anti-inflammatory drugs 
beclomethasone and nedocromil sodium on bronchial hyperresponsiveness to UNDW and 
histamine, and the effects on lung function and asthma symptom scores in allergic 
asthmatic subjects. Moreover, it is investigated whether the UNDW and histamine 
challenge tests are comparable to assess changes in bronchial hyperresponsiveness. 
(chapters 7 and 8). 
7. To investigate the relationship between asthma symptom scores and bronchial 
hyperresponsiveness to histamine and UNDW, and to determine whether the differences 
in the underlying mechanisms of the bronchoconstrictor responses to histamine and 
distilled water are reflected in these relationships, (chapter 8) 
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CHAPTER 2 
HISTAMINE PROVOCATION TEST WITH THE APS 
DOSIMETER: REPRODUCIBILITY AND COMPARI-
SON TO THE TWO-MINUTE TIDAL BREATHING 
TECHNIQUE. 
C. Groot, P. Sweep and J. Festen. 
Submitted for publication 
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2.1 ABSTRACT 
The Asthma Provocation System (APS) by Jaeger (Würzburg, FRG) is a breath-
actuated dosimeter frequently used in routine lung function laboratories for the assessment 
of bronchial hyperresponsiveness. We investigated the reproducibility of the histamine 
provocation test with the APS system in nine asthmatic subjects. The repeated histamine 
provocation tests on two different days showed a good reproducibility with a standard 
deviation for repeated measurements of 10.4%. The APS dosimeter technique was further 
compared with the 2-minute tidal breathing technique with the Wright nebulizer. In fifteen 
patients suspected for bronchial hyperresponsivenesse a histamine challenge with the two 
techniques was performed on two different days. Both techniques showed a good 
correlation (r=0.93, p<0.0005) and equally distinguised hyperresponsive from non-
hyperresponsive subjects. The limit of agreement (-103 % and +83 %) and 95% confi-
dence limit (+27%) of the two techniques, however, show that the results of the APS 
dosimeter and tidal breathing technique do not completely agree with each other. 
2.2 INTRODUCTION 
In 1985, Jaeger (Wurzburg, FRG) introduced the Asthma Provocation System 
(APS), a breath-actuated dosimeter designed for accurate dosage in bronchial challenges. 
During inspiration the aerosol is delivered instantenously after inspiration and a few maxi-
mal inspiratory capacity breaths are sufficient to deliver 45 μΐ of the aerosol. The APS is 
frequently used in Europe, and according to the information of the manufacturer, 60 to 70 
per cent of all lung function laboratories in the Netherlands use the APS. However, the 
system has not validated yet. Therefore the aim of this study was to investigate the repro­
ducibility of the histamine provocation test with the APS dosimeter. Another aim was to 
compare the histamine provocation test using the APS by the method described by Har-
greave et al. ', using a Wright nebulizer during 2-minute tidal breathing, a worldwide 
accepted and validated method of bronchial challenge. 
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2.3 PATIENTS AND METHODS 
Subjects. The reproducibility of the dosimeter technique was investigated in nine 
patients with bronchial asthma 2, whose characteristics are shown in table 2.1. 
On two different days the subjects performed a histamine provocation test with the APS 
dosimeter. 
The comparison between the dosimeter and tidal breathing technique was investi­
gated in fifteen patients suspected for bronchial hyperresponsiveness, whose characteris­
tics are shown in table 2.2. 
Table 2.1: Patient characteristics of the dosimeter reproducibility study in histamine provocation. 
patient 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
mean 
SE 
sex 
M 
M 
M 
F 
F 
F 
M 
F 
F 
age 
(У) 
50 
41 
35 
21 
26 
24 
25 
39 
30 
32.2 
3.4 
FEV, 
(% pred) 
60.5 
57.7 
80.7 
100.6 
75.2 
84.5 
91.9 
95.9 
101.6 
83.6 
5.7 
PD^H, 
(*) 
(μιηοΙ) 
0.02 
0.10 
0.14 
0.25 
0.31 
0.33 
0.62 
1.48 
1.78 
0.56 
0.21 
PD.H, 
(μπιοί) 
0.01 
0.05 
0.25 
0.39 
0.50 
0.32 
0.32 
1.62 
1.59 
0.56 
0.20 
medication 
С') 
s, ie 
s, ie 
s, ie 
s, ie 
s 
s 
s 
s 
s 
(*) PDJOH] and PDJJHJ: The PDj, values of the histamine challenges on day 1 and day 2. 
(**) s = salbutamol; ie = inhaled corticosteroids. 
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Table 2.2: Patient characteristics of the comparison of the dosimeter tedmique versus the 2-minute tidal 
breathing tedmique in histamine bronchial challenge. 
patient 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
15. 
mean 
SE 
sex 
F 
F 
F 
F 
M 
M 
F 
M 
M 
M 
F 
F 
F 
M 
M 
age 
(У) 
39 
53 
39 
61 
15 
26 
73 
26 
27 
44 
48 
47 
27 
47 
24 
39.1 
4.0 
FEV, 
(% pred) 
95.5 
84.6 
92.7 
109.4 
77.0 
92.2 
54.8 
93.7 
76.7 
87.4 
62.5 
101.3 
96.7 
67.9 
99.0 
86.1 
4.0 
P D , 
C) 
(mg/ml) 
5.6 
12.6 
11.6 
0.02 
0.22 
10.4 
2.2 
5.2 
0.80 
0.50 
16.0 
8.4 
>16 
>16 
>16 
P C , 
(mg/ml) 
3.5 
9.1 
16.0 
0.02 
0.32 
16.0 
2.5 
1.4 
0.36 
2.9 
15.0 
13.2 
>16 
>16 
>16 
medication 
. 
-
b 
ic 
b 
-
b 
b 
-
ic 
op 
-
-
-
-
(*) 1 mg/ml histamine = 0.15 μπιοί histamine. 
(**) b = ^2. agonist; ic = inhaled corticosteroids: op = oral prednisone; 
On day 1 the subjects performed a provocation test with the dosimeter and on day 2 a 
provocation test with the 2-minute tidal breathing procedure. The baseline FEV, values on 
the two study days in both groups of patients were within 10% variation, all medication 
was stopped for a period of more than twelve hours before the test and the tests were 
performed at the same time of the day. None of the patients used theophylline. The proto­
col was approved by the Local Ethics Committee. 
The APS dosimeter technique. The APS (Jaeger, Würzburg, FRG) (figure 2.1) 
consists of a breathing-unit, with a deadspace of 35 ml, in- and expiration valves, the 
Sandoz 1500 nebulizer with a very low variation in output and an expiration filter to col-
lect the histamine aerosol. The output of the nebulizer is not affected by the liquid level 
in the nebulizer container. The aerosol particle size varies from 1.9 to 5.6 microns. The 
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mobile control unit adjusts the number of inhalations, the nebulization time, and the dosa­
ge interval. The compression unit consists of a high-pressure pump, an adjustable low-
pressure reservoir for a constant nebulization pressure and a manometer. The pressure 
used in our investigation was 200 kPa. Depending on the output of the nebulizer contai­
ner, six to eight maximal inspirations were used to deliver 45 μΐ of histamine per dose. 
The nebulization time was 0.6 seconds per breath and the aerosol was delivered within 
0.1 second after the beginning of an inhalation. Inhalation of 45 ді of a concentration of 1 
mg/ml histamine resulted in a dose of 0.15 μπιοΐ. 
The tidal breathing technique. The aerosol was generated by a Wright nebulizer 
according to the method described by Hargreave et al. ', with a nebulizer output of 130 
+. 4 μΐ/min, at an airflow of 7 1/min. Subjects wearing a noseclip and face mask, inhaled 
the histamine for two minutes during tidal breathing. 
Figure 2.1: The asthma provocation sysytem consist of a breathing unit (A), a mobile controle unit (B), and 
a compression unit (C). 
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Provocation protocol. After inhaling of phosphate acid buffered saline, doubling 
concentrations of histamine acid phosphate (0.03 - 16.0 mg/ml) were administered at five-
minute intervals. The test was stopped after the last dose of histamine, i.e. 16 mg/ml, had 
been inhaled or a fall in FEV, of more than 20% had been achieved. The PDJiistamine, 
the dose of histamine causing a 20% fall in FEV, from baseline values, was calculated for 
the APS method, whereas for the tidal breathing-method the PCJiistamine, concentration 
of histamine causing a 20% fall in FEV, from baseline values, was calculated. The PD» 
and PO,, values were obtained from a semi-logarithmic dose-response curve by linear 
interpolation. 
Lung fimction. Flow-volume curves were recorded on a pneumoscreen Π (Jaeger, 
Würzburg, FRG), 30 and 90 seconds after inhalation. If a decrease of FEV, of 20% or 
more occurred the challenge was discontinued. 
Statistical analysis. All data are presented as mean ±_ standard error (SE). The 
baseline FEV, is expressed as percentage of predicted \ The Student-t test was performed 
on the FEV, values. The PD» and PC» values were log transformed before further analy-
sis. Correlations were calculated by the Pearson coefficient. The standard deviation for 
repeated measurements, limit of agreement and confidence intervals were calculated ac-
cording to Bland et al \ Significance was accepted for ρ < 0.05. 
2.4 RESULTS 
The baseline FEV, values on the two study days were not significantly different in 
either of the investigations. 
Repeated histamine provocation tests performed with the APS dosimeter resulted in a 
mean PDJiistamine on day one of 0.56 +. 0.21 дтоі and on day two of 0.56 +. 0.20 
μιηοΐ (table 2.1). All PDj,, values were within one doubling dose as shown in figure 2.2. 
The correlation between the repeated histamine provocation tests was r=0.95 and p<0.0-
005, with a standard deviation for repeated measurement of 10.4%. 
In the study comparing the APS dosimeter with the 2-minute tidal breathing tech­
nique patients 1-12 showed a 20% fall in FEV, after inhaling of the last dose of histam-
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ine, i.e. 16 mg/ml. The mean PD^histamine and PCjohistamine in these patients were 
6.1±1.6 and 6.7.+ 1.9 mg/ml respectively. Those who responded to histamine (pat. 1-12) 
were used for calculating the correlation and limit of agreement between the two tests. 
Patients 13-15 did not respond. Both the dosimeter and tidal breathing technique could not 
induce a 20% fall in FEV, in these patients. 
Figure 2.3 shows the correlation between the PCj, and РО
ш
 values (r=0.93, p=0-
.001). The limits of agreement for the PD» compared to the PC» are -102 % and +83%, 
with a 95% confidence interval of + 27 %. 
PD2ohistamine-1 [pmol] 
Figure 2.2: The reproducibiUty of Ute PDJiistamine paformed with the APS dosimeter. Vie dashed Unes 
represents the Une of identity ±_ one doubling dose. AU values are within one doubling dose. The standard 
deviation for repeated measurements is 10.4%. 
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Figure 2.3: The correlation between the PDJiistamine, performed with the APS dosimeter and maximal 
inspiratory breaths, and the PCJiistamine, performed with the Wright nebulizer during two-minute tidal 
breathing. 
2.5 DISCUSSION 
The APS dosimeter technique showed a good reproducibility. A high correlation 
and a low standard deviation for repeated measurements was found, with all PDj,, values 
within one doubling dose when the test was repeated in asthmatic subjects. The reprodu-
cibility of the APS technique is comparable to that of the 2-minute tidal breathing techni-
que \ 
The data in this chapter show that both tests equally distinguished between respon-
ders and non-responders, subjects who did not reach a 20% fall in FEV, after inhaling 16 
mg/ml histamine, and between hyperresponsive and non-hyperresponsive subjects, with 
the cut-off point of 8 mg/ml'. Furthermore, a good correlation exists between both test 
methods. However, it would be inaccurate to state that the APS, using a few maximal 
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inspirations, and the Wright nebulizer, using tidal breathing for two minutes, are fully 
comparable \ The limits of agreement between the two tests and the 95% confidence 
intervals show that both tests are not completely interchangeable. Ryan et al. β compared 
the French-Rosenthal dosimeter, using maximal inspiratory inhalation, with the Wright 
nebulizer, using tidal breathing for two-minute, and demonstrated a difference in deposi­
tion of the aerosol in the lung. Also differences in the shape of the dose-response curve 
have been found comparing the Wright nebulizer and the dosimeter technique, although 
the PC» values of the two techniques correlated significantly 7. 
The tidal breathing technique is a simple and inexpensive method, although the 
following factors should still be standardized to obtain reliable results: breathing frequen­
cy, flow rate, inspiration volume and breath holding time. These factors influence the 
inhaled dose in this method * while they are not constant during tidal breathing '. The 
dosimeter technique is a more sophisticated, more expensive method, which has the ad­
vantage that the inhaled dose of the agent is known exactly. The amount of drug delivered 
to the airways is also not influenced by the breathing pattern. 
We conclude that the APS dosimeter technique is a good reproducible method and 
comparable to the tidal breathing technique with the Wright nebulizer, with regard to the 
reproducibility and assessment of bronchial hyperresponsiveness to histamine. The limits 
of agreement between the two techniques, however, show that the results are not comple­
tely interchangeable and must be interpreted carefully. 
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3.1 INTRODUCTION 
Bronchial provocation tests are standardized methods to measure and quantify 
bronchial hyperresponsiveness. Usually, inhalation tests with histamine or methacholine 
are used and their importance for the diagnosis and assessment of disease severity in 
asthma and chronic obstructive pulmonary disease has clearly been demonstrated '•I. 
Inhalation of non-isotonic aerosols can also cause bronchoconstriction in 
hyperresponsive patients as De Vries et al. demonstrated in 1964 in his test with cooled 
steam 4. Steam was led into cold air to produce fog with a temperature of -10°C. 
Inhalation of this fog induced a bronchoconstrictor response in subjects with bronchial 
hyperresponsiveness 4. 
After the introduction of the ultrasonic nebulizers in the 1960's, larger amounts of 
aerosols could be nebulized and deposited in the airways. In high-frequency ultrasonic 
nebulizers with a transducer frequency of above 0.5 mHz, the output is a function of the 
input power to the transducer, but little is known about factors which influence the 
droplet size in the aerosol5. 
In the first decade, ultrasonic nebulizers were used for inhalation of drugs by 
asthmatic patients and patients with cystic fibrosis ', and for humidification of air in 
mechanical ventilators 7. In 1980, however, Allegra et al. 8 introduced ultrasonically 
nebulized distilled water (UNDW) as a bronchial provocation test in asthmatic patients 
and since then several effects of hypotonic and hypertonic aerosols in normal subjects and 
in patients with asthma have been published e"'3. 
In the following paragraphs the literature on UNDW bronchoprovocation tests is reviewed 
and the mechanisms underlying the bronchoconstriction induced by inhalation of UNDW 
are discussed. Different techniques of nebulization are described as well as the correlation 
with other bronchoprovocation tests and the factors related to the refractory period. 
Furthermore, the method of the UNDW challenge test used in the studies presented in this 
thesis is described, including the reproducibility, the duration of the bronchoconstrictor 
effect and the correlation to histamine challenge. 
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3.2 HYPOTHESIS WITH RESPECT TO THE MECHANISMS OF 
UNDW-INDUCED BRONCHOCONSTRICTION 
The mechanism of bronchoconstriction induced by inhalation of UNDW has been 
extensively studied but has not been elucidated yet " · Μ . In contrast to isotonic solutions, 
inhalation of both hypotonic and hypertonic aerosols can induce bronchoconstnctor 
responses in asthmatic patients " · " . In normal subjects inhalation of aerosols of these 
solutions only induces some coughing but not bronchoconstriction 11·14·13. The non-
isotonicity of the inhaled aerosol appears to be a prerogative to elicit the bronchoconstric-
tor response ". Eschenbacher et al demonstrated that for hyperosmolar solutions an 
increase in ion concentrations is an additional stimulus for bronchoconstriction ". Two 
solutions with an osmolality of 1,232 mmol, one containing 4 % sodium chloride and one 
containing 18.3% dextrose and 1% sodium chloride, were inhaled by the same asthmatic 
subjects. Inhalation of the solution with the higher ion content shifted the dose-response 
curve to the left, thus increasing the sensitivity of the subjects to the bronchoconstnctor 
stimulus. 
An increased acidity of the nebulized solution can significantly enhance the 
bronchoconstrictor potency of hypoosmolar aerosols ". Furthermore, the titratable acidity 
of the inhaled aerosol is important ". Inhalation of buffered solutions of HCl and H2S04 
induced a significant bronchoconstriction in 8 asthmatic subjects, whereas inhaled 
unbuffered HCl caused a bronchoconstrition in only one patient and unbuffered H2S04 had 
no effect. The pHs of all solutions were identical ". Sulphuric acid and hydroxymethane-
sulphonic acid, both of them common constituents of acid fogs, had no specific broncho­
constnctor effects in asthmatics " · " . Alkaline aerosols inhaled by mild asthmatic subjects 
did not induce bronchoconstriction ", 
An increase in temperature of the nebulized solution from 20 to 37 "C may 
diminish the bronchoconstrictor effect of distilled water aerosols, but not of aerosols of 
hypertonic solutions 2I. This finding, however, has not been confirmed by other investiga­
tors '. The degree of bronchoconstriction induced by these aerosols is also influenced by 
the inspiratory flow rate, since increasing the inspiratory flow rate to 1.2 1/s with constant 
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volume diminished the UNDW-induced bronchoconstrictor response when compared to 
the flow rate at tidal breathing n . The increased flow rate probably changes aerosol 
deposition in the airways. 
Bronchoconstriction induced by the inhalation of non-isotonic aerosols appears to 
be caused to a considerable degree by the osmolar changes in the airway epithelium. 
Acidity of the solution and titratability of the acid increases the bronchoconstrictor 
response, while the temperature of hypotonic aerosols may also be important. 
Sheppard et al. '0 demonstrated a clear decrease in UNDW-induced bronchocon-
triction after pretreatment with 0.2 and 2.0 mg of inhaled atropine sulphate in asthmatic 
subjects. The two doses of atropine caused a similar reduction in baseline airway 
resistance, but the higher dose was significantly more effective in reducing the UNDW-
induced bronchoconstriction. Studies with inhaled ipratropium bromide at doses of 40 μ% 
and 80 jug e , n did not show any effect of pretreatment with this muscarine receptor 
antagonist on UNDW-induced bronchoconstriction. High doses of ipratropium bromide, 
up to 2000 Mg, could inhibit the UNDW-induced bronchoconstrictor response u. To 
investigate dose-dependency receptor blockade on UNDW response we studied the 
protective effects of 160 ßg and 320 pg ipratropium bromide in 9 asthmatic patients. The 
results are described in chapter 5. Our data and the data reported in literature suggest at 
least a partial involvement of the parasympathetic nervous system and/or the muscarinic 
receptors on the airway smooth muscles in the UNDW-induced bronchoconstrictor 
response. 
Although 4% lidocaine partially inhibits the coughing usually caused by inhalati-
on of distilled water ", it did not inhibit bronchoconstriction 10. This, however, does not 
exclude involvement of afferent vagal nerves, since it is difficult to block all sensory 
nerve endings in the airways of asthmatic patients with inhaled local anaesthetics because 
of the risk of anaesthesia-induced bronchoconstriction in these patients и . Moreover, it 
has recently been shown in normal subjects, that the bronchodilator properties of inhaled 
capsaicin, a strong stimulator of vagal afferent nerve fibres, could be blocked by inhaled 
lidocaine, whereas the capsaicin-induced brochoconstriction was not influenced *. 
Stimulation of vagal afferent nerve endings can also cause a local axon reflex in the 
airway wall n . This induces the release of neuropeptides from sensory nerve endings with 
38 
Chapter 3 
both bronchoconstrictor and bronchodilator properties. These local axon reflexes may well 
play a role in UNDW-induced bronchoconstriction as well. Inhaled morphine can inhibit 
UNDW-induced bronchoconstriction in asthmatic subjects and this effect is correlated to 
atropine inhibitory effects, suggesting that morphine inhibits a vagally mediated broncho-
constrictor response to UNDW a . Opiate receptors are located throughout the central and 
peripheral nervous system, but the location at which morphine inhibits the UNDW-
induced bronchoconstriction is uncertain a . 
At present, it seems that the autonomic nervous system of the airways is involved in 
UNDW-induced responses, but it is unclear to what extent. 
The release of mediators from inflammatory cells plays an important role in the 
acute and late-phase asthmatic response ", In UNDW-induced bronchoconstriction these 
mediators also appear to be involved 3W1. In vitro, it has been demonstrated that rat mast 
cells release preformed mediators like histamine and neutrophil chemotactic activity when 
suspended in a hypotonic solution 3\ Inhalation of UNDW in asthmatic patients causes an 
increase in blood neutrophil chemotactic activity, whereas no such change could be 
demonstrated in normal subjects ". Serum histamine levels were also elevated in these 
patients, but there was no significant difference in the serum histamine response between 
normals and asthmatics. Local hypoosmolar challenge to airway segments of four 
asthmatic patients by bronchoalveolar lavage through a flexible bronchoscope resulted in 
the release of histamine into the airway fluid, while lavage with normal saline did not 
have such an effect 33. Pretreatment with terfenadine, a specific H, receptor-antagonist, 
could diminish the UNDW-induced bronchoconstrictor response 34'M, indicating that H,-
receptor activation by histamine plays a role in UNDW-induced bronchoconstriction. 
Pretreatment with disodium cromoglycate '·14 and nedocromil sodium M completely blocks 
the bronchoconstrictor response to UNDW exposure in asthmatics. These drugs are 
supposed to inhibit mediator release from inflammatory airway cells ", which indicates 
involvement of these cells in UNDW-induced bronchoconstriction. On the other hand, 
both drugs have so-called "non-mast-cell effects", as they inhibit vagally induced 
bronchoconstriction by inhaled sulphur dioxide in man M. 
Leukotrienes D4 and E4, arachidonic acid metabolites synthesized in inflammatory 
cells during asthmatic reactions, may also be important in the UNDW response, since 
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specific antagonists of these leukotrienes can diminish bronchoconstriction induced by 
UNDW. ". 
In table 3.1 summarizes the protective effects of different drugs on the UNDW-induced 
bronchoconstrictor response. 
Table 3.1: Protective effects of drugs on the UNDW-induced brondioconstriaor response. 
drug dose time between 
dose and test 
degree of 
protection 
reference 
sodium 
cromoglycate 
nedocromil 
sodium 
atropine 
ipratropium 
bromide 
salbutamol 
fenoterol 
clenbuterol 
terbutaline 
theophylline 
nifedipine 
10 mg 
12 mg 
20 mg 
20 mg 
40 mg 
4 mg 
8 mg 
0.2 mg 
2.0 mg 
0.04 mg/kg 
40 μg 
80 μg 
160 μ 6 
320 μ
ε 
200 μ 8 
1000 μ 8 
2000 μ 8 
200 μ 8 
200 μ 6 
200 μ 8 
200 μ 8 
200 μ 8 
400 μg 
400 μ 8 
40 μg 
500 μ 8 
10 mg/kg" 
20 mg" 
10 mg" 
30 min 
30 min 
10 min 
30 min 
20 min 
30 min 
30 min 
15 min 
15 min 
20 min 
30 min 
60 min 
30 min 
30 min 
90 min 
90 min 
90 min 
60 min 
2,4,6 hrs 
4hrs 
30 min 
2 hrs 
20 min 
2,4,6 hrs 
4 hrs 
30 min 
4,8,12 hrs 
45 min 
20 min 
+ 
+ 
+ + 
+ 
+ + 
+ + 
+ + 
_ 
+ 
+ 
_ 
-
-
+ 
+ 
+ 
+ 
+ + 
+ 
+ 
+ + 
+ + 
+ + 
+ + 
+ + 
+ 
+ 
+. 
+ 
40 
41 
9 
42 
8 
36 
41 
10 
10 
43 
23 
8 
chapter 5 
chapter 5 
24 
24 
24 
8 
44 
45 
23 
44 
25 
44 
45 
chapter 5 
46 
25 
44 
40 
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Table 3.1. (continued) 
drug 
verapamil 
tiaraimde 
chlorpheniramide 
maléate 
ranitidine 
furosemide 
indomethacm 
lidocaine 
LY 171883 
(leukotnene 
antagonist) 
morphine 
terfenadine 
dose 
12.5 mg 
100 μ
ε 
200 μ 8 
400 μg 
б mg 
12 mg 
25 mg 
40 mg 
100 mg* 
4% 
400 mg' 
(7 days) 
0.15 mg\kg 
120 mg" 
180 mg" 
240 mg" 
time between 
dose and test 
15 mm 
1.2,4 hrs 
,, 
,, 
2 hrs 
2 hrs 
20 mm 
direct 
2 hrs 
(3 days) 
direct 
2 hrs 
30 mm 
4 hrs 
2'A hrs 
4 hrs 
degree of 
protection 
± 
+ + 
+ + 
+ + 
-
-
-
+ + 
-
-
+ 
+ 
+ 
+ 
+ 
reference 
9 
9,10 
9,10 
44 
44 
44 
47 
48 
10 
39 
28 
34 
35 
34 
All medication was administered by inhalation, unless indicated otherwise. (* : medication used orally, ** 
medication used sublmgually). 
Degree of protective effects: 
- : no protection 
+_ : protection in some patients 
+ : significant protection for all patients 
+ + : totally blocked broncho-constnctor response. 
In conclusion, the mechanism of UNDW-induced bronchoconstriction is probably 
multifactorial, including osmolar changes in the airway epithelium, mediators released 
from inflammatory cells, and vagal reflex mechanisms. 
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3.3 METHODS OF UNDW CHALLENGE 
A number of different methods is used for bronchial provocation tests with 
ultrasonically nebulized aerosols. DeVries et al. demonstrated in 1964 bronchoconstrictor 
responses to cooled steam in asthmatic patients 4. In 1980, Allegra and Bianco ' introdu-
ced a standardized provocation test with UNDW. They challenged the patients with a 
single dose of aerosol with a nebulizer output of 2 ml/min. The aerosol was inhaled for 5 
minutes through a face mask at tidal breathing. A modification of this test with multiple, 
increasing doses of aerosol, created the opportunity to construct a dose-response curve ". 
To achieve increasing doses the nebulization time was doubled at a fixed output of 2 
ml/min. Consecutive nebulizations of 30, 60, 120, 240 and 480 seconds were given 44·'". 
Schoeffel et al. ,4 measured the volume of inhaled aerosol and administered increasing 
doses of distilled water by doubling the inhaled volume at a fixed output of 2 ml/min., 
and 5, 10, 20, 40, and 80 liter were given successively. Sheppard et al. 10 achieved 
increasing doses by doubling the output of the nebulizer at a fixed inhalation time of 3 
minutes (0.4, 0.7, 1.5, 3.1 and 5.4 ml/min). 
Thus, four different techniques are presently used for bronchial provocation tests 
with inhaled aerosols of distilled water. A comparison of the efficacy of these different 
techniques has not been performed. Differences in ventilation rate between subjects and 
during challenging within the same subject " suggest that volume-dependent doses used in 
bronchial challenge with ultrasonically nebulized aerosols are a reliable technique to 
construct dose-response curves '. We have therefore chosen a volume-dependent method 
of UNDW challenge in the studies presented here. 
3.4 CORRELATION BETWEEN U N D W AND OTHER BRONCHI-
AL CHALLENGES 
Several studies have been performed to investigate the relation between the 
UNDW provocation tests and other bronchial challenge tests. In this paragraph we shall 
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give a review of the literature on this issue and discuss the results. 
Methacholine. In a group of 20 atopic asthmatic children no correlation could be 
found between the fall in FEV, induced by inhaled methacholine and UNDW 5'. Neither 
in a group of 25 asthmatic subjects ,aged 9-19, no correlation was found between 
POaUNDW, the nebulizer output of UNDW causing a 20% fall in FEV,, and the 
PCainethacholine, the concentration of methacholine causing a 20% fall in FEV, я . In a 
group of 15 asthmatic adults, a weak though significant correlation (r=0.54, ρ < 0.05) 
was established between the PD^methacholine and the PD^UNDW a. In another group of 
38 asthmatic aldults an also significant correlation was demonstrated between the 
methacholine and UNDW challenge (r=0.62, p<0.0001), with a threshold expressed as 
area under the curve ". Anderson et al. could not find a correlation between the PD^met-
hacholine and PD^UNDW in a group of 15 asthmatic subjects *. However, when they 
increased the number of patients to 20 a significant correlation between PD^methacholine 
and PDaUNDW (r=0.60, p<0.01) was found ". In children, who seem to be less 
susceptible to UNDW-induced bronchoconstriction 5I·56·", the relationship between 
bronchoconstriction induced by distilled water inhalation and methacholine is probably 
different from that in adults. 
Histamine. Fewer studies have been performed to compare the histamine- and 
UNDW-induced bronchoconstrictor response. In 20 asthmatic children sensitive to 
histamine, only five patients showed an UNDW-induced bronchoconstriction, and 
apparently no correlation was found ". Anderson et al. did not find a correlation between 
the PDjoUNDW and PCJiistamine in 16 adult asthmatic patients *. There was an interval 
of more than 24 days between the two tests in some patients, which may have contributed 
to the lack of correlation. Rosati et al., however, found a significant correlation (r,=0.45, 
ρ < 0.001) between histamine and UNDW challenge in 87 asthmatic patients я . 
Exercise. Several authors have investigated the relationship between exercise-
and UNDW-induced bronchoconstrictor responses. In 17 atopic asthmatic subjects a 
significant correlation was found between the maximal fall in FEV, after exercise and the 
PO^UNDW (r=-0.66, ρ<0.01), whereas in this group of patients no correlation was 
found between UNDW and methacholine challenge testing 32. Bascom et al. also found a 
highly significant correlation between exercise and UNDW in 15 asthmatic subjects 
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(r.=0.81,p<0.001), with a weaker correlation between UNDW and methacholine, and 
between exercise and methacholine (r,=0.54 and r,=0.49, respectively) a. In 7 asthmatic 
subjects no difference was found between the fall in FEV, after inhalation of UNDW and 
exercise w . Because of these correlations between UNDW challenge and exercise, and 
because of the similarrity in bronchoconstrictor mechanism between both stimuli (mast-
cell-derived mediators play also an important role in exercise-induced bronchoconstrcition 
"О a common pathway for exercise- and UNDW-induced bronchoconstriction has been 
suggested 42,Si,iD. In children, however, there is no relation between exercise and UNDW 
challenge, which casts some doubt on this hypothesis *•". 
Hyperventilation with cold air. As the result of the studies investigating the 
influence of air temperature during exercise-induced bronchoconstriction ' l l·6 2, hyperventi­
lation with cold air has been proposed as bronchial provocation test in asthmatic subjects. 
Comparison of the cold air hyperventilation- and UNDW-induced bronchoconstrictor 
responses showed a good correlation between the fall in FEV, after both stimuli in nine 
asthmatic patients (г=0.89,р<0.01) 0 . In another study of 11 asthmatic subjects, 
however, only a weak correlation was found between the PD^UNDW and the minute 
ventilation causing a 20% fall in FEV, (r,=0.51,ρ< 0.05) ", In children no correlation 
has been established between cold air hyperventilation and inhalation of UNDW ". 
Hypertonic saline. No correlation was found between the PD^UNDW and the 
PD» for 4.5% saline". 
Conclusion. We conclude that in adult asthmatic patients a correlation can be 
found between the methacholine- or histamine-induced bronchoconstriction and the 
bronchoconstrictor response to UNDW. Also exercise and cold air hyperventilation-
induced bronchoconstriction are correlated to the UNDW-induced bronchoconstrictor 
effect. The correlations between exercise and UNDW are higher than the correlations 
between methacholine and UNDW, probably indicating a similar pathway for exercise-
and UNDW-induced bronchoconstriction. No correlation was found between UNDW and 
hypertonic saline challenge, although a similar mechanism of bronchoconstriction for 
hypertonic saline and cold air hyperventilation has been proposed ". This needs further 
evaluation. 
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3.5 THE REFRACTORY PERIOD 
Certain asthmatic patients responding to UNDW demonstrate a significant 
attenuated response after re-exposure to UNDW within several hours after the first 
challenge ' ,67'e. This phenomenon, known as refractoriness, has been demonstrated in 
provocation tests with other physical stimuli like exercise M and hypertonic aerosols ™. In 
some provocation tests with pharmacological stimuli, this phenomenon can also be 
demonstrated and is called tachyphylaxis "'л. 
The mechanism of refractoriness has not been elucidated yet. Pretreatment with 
the cyclooxygenase inhibitor indomethacin can totally abolish the refractory period after 
repeated inhalation of UNDW *. This indicates that prostaglandins with bronchodilator 
properties such as PGEz are probably involved in the phenomenon of refractoriness. 
Mattoli et al. " found a correlation between the recovery rates of the FEV, after UNDW 
and methacholine challenge and the presence of refractoriness. Patients with a refractory 
period for UNDW recovered more rapidly from UNDW- and methacholine-induced 
bronchoconconstriction than non-refractory patients ", In these patients bronchodilator 
mechanisms counteracting the bronchoconstriction may well be more pronounced or less 
affected by airway disease in asthma. 
Increase in bronchial hyperresponsiveness after preinhalation of UNDW has been 
the subject of interest of several investigators. UNDW-induced bronchoconstriction 
followed by a histamine or methacholine provocation test, when the FEV, had spontane­
ously returned to the baseline value, showed an increase in bronchial hyperresponsiveness 
to histamine and methacholine 74, whereas hypertonic saline-induced bronchoconstriction 
showed no effects on bronchial hyperresponsiveness ". Furthermore, other authors found 
that the UNDW-induced increase in bronchial hyperresponsiveness to methacholine was 
related to the absence of a refractory period for repeated inhalation of UNDW ". The 
increase in bronchial hyperresponsiveness to methacholine after prior UNDW challenge 
waned off within two hours in the majority of patients, except for two out of ten patients, 
who developed a late-asthmatic reaction after UNDW challenge ". This late response was 
less severe than the initial response and the decrease in FEV, lasted four to five hours. 
45 
Chapter 3 
Eight hours after UNDW challenge there was still an increase in bronchial hyperresponsi-
veness to methacholine in the patients with a late-asthmatic reaction '\ Prevention of the 
UNDW-induced bronchoconstictor response by preinhalation of cromolyn sodium also 
inhibitted the increase in bronchial hyperresponsiveness to methacholine и . 
Comparison of the refractory period after exercise and inhalation of UNDW 
showed a similar pattern of diminished bronchoconstriction in 14 asthmatic subjects e . 
Cross-refractoriness could be demonstrated if an exercise test was followed by an UNDW 
challenge, indicating a final common pathway in the mechanism of refractoriness for 
exercise and UNDW inhalation m. 
Preinhalation of histamine before exercise testing " or UNDW challenge '3 can also 
induce a refractory period, which will be discussed in detail in chapter 4. 
Thus, refractoriness for repeated provocation tests with UNDW can be blocked 
by pretreatment with indomethacin, indicating involvement of the cyclooxygenase pathway 
and release of bronchodilator prostaglandins. The refractoriness is related to a more rapid 
recovery from the UNDW- and methacholine- induced bronchoconstrictor response. 
Refractoriness after inhalation of UNDW is similar to refractoriness after exercise, 
indicating a final common pathway. The absence of a refractory period after repeated 
UNDW challenge is related to an increase of bronchial hyperresponsiveness to histamine 
and methacholine following UNDW-induced bronchoconstriction. 
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CHAPTER 4 
THE UNDW BRONCHOPROVOCATION TEST 
C.A.R. Groot, J-W.J. Lammers, J. Festen and C.L.A. van Herwaarden 
in part submitted for publication (paragraph 4.3 and 4.4) 
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4.1 THE UNDW BRONCHOPROVOCATION PROTOCOL USED 
IN THE PRESENT STUDIES 
The bronchoprovocation test with UNDW in the present studies was performed 
according to a modification of the method of Schoeffel et al. '. To increase the sensitivity 
of the test the number of doubling doses were expanded. The interval between two 
consecutive doses was extended from 2 to 5 minutes as a result of a study of the duration 
of the UNDW-induced bronchoconstrictor response described in paragraph 4.4. The 
distilled water aerosol was generated by a Ultraneb 99 ultrasonic nebulizer (DeVilbiss, 
Somerset, USA). The level of distilled water in the nebulizer chamber was kept constant 
by means of a float and by continuous infusion of distilled water. The output of the 
nebulizer was fixed at 2.00 +. 0.05 ml/min aerosol generation in free space. 
UNDW was inhaled at tidal breathing through a mouthpiece with tightened lips 
and nose clipped. A Leardal IV two-way valve (Stavanger, Norway), with a dead space 
of 24 ml, was placed between the aerosol hose and the mouthpiece. A respirometer 
(British Oxygen Company, London, UK) was connected to the expiratory port of a two-
way valve to measure the total volume of inhaled air. After inhalation of 20 liters of 
ambient air through the system, doubling volumes of air with UNDW (3, 5, 10, 20, 40, 
80, and 160 L) were inhaled at 5-minute intervals. Before and after the test the nebulizer 
chamber and aerosol hose were weighed and the total amount of inhaled distilled water 
was measured. 
To assess bronchoconstriction, flow-volume curves were recorded 30, 90 and 180 
seconds after inhalation by means of flow-volume equipment containing a 
pneumotachograph (Pneumoscreen II, Jaeger, Würzburg, FRG). If the FEV, at 180 
seconds was lower than the FEV, values recorded at 30 or 90 seconds, further flow-
volume curves were recorded until the FEV, increased spontaneously, in order to obtain 
the deepest fall in FEV,. The test was stopped when a 20% fall in FEV, had been 
achieved or the last dose of air with UNDW, i.e. 160 1 had been inhaled. 
The PDJOUNDW, the cumulative dose of UNDW causing a 20% fall in FEV,, 
was calculated from post-air values by linear interpolation on a semi-logarithmic dose-
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response curve and was expressed in ml HjO. 
4.2 THE ULTRANEB 99 
The ultrasonic nebulizer used in our studies was the Ultraneb 99 (DeVilbiss, 
Somerset, USA) shown in figure 4.1. 
Figure 4.1: The ultrasonic nebulizer (A). The aerosol hose was connected to the inspiratory port of a two-
way valve (B). A respirometer (C) was connected to the expiratory port to measure the volume of inhaled air 
with UNDW. 
Specifications: transducer frequency 1.63 MHz 
output: 0 - 7.5 ml/min 
droplet size: 0.5 - 5.0 μ 
median mass diameter: 2.8 μ 
fan flow: 12 1/min 
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4.3 REPRODUCIBILITY OF THE UNDW-INDUCED BRONCHO-
CONSTRICTOR RESPONSE 
Introduction 
The dose-response curve describes the relationship between the dose of a 
stimulus and the stimulus-induced response. In bronchial challenge, the dose-response 
curve is often used to determine the degree of bronchial hyperresponsiveness in asthmatic 
patients 2. Woolcock et al. investigated changes in the shape of the dose-response curve 
on histamine inhalation in asthmatic and normal subjects and demonstrated that the dose-
response curves of asthmatic patients are shifted to the left in comparison with non-
asthmatics. Moreover, there is an increase in the slope of the curve and the maximal 
bronchoconstrictor response (figure 4.2)3. 
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Figure 4.2: Dose-response curves of histamine-induced bronchoconstriction in normals (A), mild asthmatics 
(B) and more severe asthmatics (C), a modification to Woolcock et al y. The shaded area indicates the part 
of the bronchoconstrictor response usually measured in vivo. 
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Theoretically, a distinction between pre- and post-junctional mechanisms has been 
proposed with regard to changes in the dose-response curve *\ The leftward shift of the 
dose-response curve may well be the result of a pre-junctional mechanism, whereas an 
increase in maximal airway narrowing is suggested to be the result of a post-junctional 
phenomenon in the effector organ ^4. In clinical practice, the dose-response curves are 
usually limited to a 20% fall in FEV,, indicated by the shaded area in figure 4.2, and no 
information is available with regard to the maximal obtainable level or plateau of airway 
narrowing. As mentioned above, Woolcock et al. 3 found that the more bronchial 
responsiveness increases, the steeper the slope of the dose-response curve and the higher 
the plateau of maximal airway narrowing on histamine are. This slope of the dose-
response curve is theoretically identical to the reactivity, defined as the slope of the 
steepest part of the dose-response curve 5. One may speculate that if there is a relation 
between the slope of the curve and the level of maximal airway narrowing, the reactivity 
of the curve may give some information about the maximal degree of airway narrowing. 
% FEV, 
100 
PD20UNDW 
Figure 4.3: Λ dose-response curve of the UNDW-induced brondìoconstrìctor response. The PD^UNDW, the 
cumulative dose of inhaled distilled water causing a 20% fall in FEV,, and the area under the UNDW dose-
response curve, indicated by the shaded area are presented. 
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To quantify the UNDW-induced bronchoconstriction several thresholds such as 
PDJOUNDW ', the area under the dose-response curve ' and the maximal fall in FEV, ' 
may be used. However, the shape of the dose-response is not expressed by these 
thresholds. We therefore measured both the sensitivity of the dose-response curve, which 
is a linear regression of the total dose-response curve ', and the reactivity of the dose-
response curve, which is the slope of the steepest part of the curve '. 
To validate the UNDW provocation test for the measurement of bronchial 
hyperresponsiveness in asthma we investigated the reproducibility of the UNDW-induced 
bronchoconstrictor response, with regard to the PD^UNDW, the area under the curve, the 
sensitivity and the reactivity of the dose-response curve, and with regard to the relations-
hips between these parameters. 
Figure 4.4: Vie sensitivity (A), the slope of a linear regression of the total dose-response curve, and the 
reactivity (B), the steepest slope of the dose-response curve are indicated on a UNDW-induced bronduon-
strictor response. 
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Patients and methods 
Thirty-three stable asthmatics, with a reversibility of their baseline FEV, of more 
than 15 % after inhalation of a flî-agonist and known responsiveness to UNDW inhalati-
on, participated in the studies. Twenty-nine asthmatic subjects were atopic, defined as two 
or more positive skin reactions to a panel of common airborne allergens. The short-term 
reproducibility of the UNDW dose-response curve, within an interval of 3 weeks, was 
investigated in 17 patients, group A (Table 4.1). 
0.1 1.0 10.0 100 0.1 1.0 10.0 100 
PDÎOUNDW-I [mil PD2oUNDW-1 [ml] 
Figure 4.5: Short-term reproducibility (panel Λ) and long-term reproducibility (panel B) of the PD^fTNDW. 
The unbroken Une is the Une of identity, the broken Une represents one doubUng dose. The standard 
deviation for repeated measurements is 32.3% for short-term and 36.9% for long-term reproducibility. 
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Table 4.1: patient characteristics, group A 
patient 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
15. 
16. 
17. 
mean 
SE 
age 
(У) 
54 
38 
34 
39 
45 
31 
46 
37 
18 
19 
39 
25 
30 
26 
49 
21 
41 
34.8 
2.6 
sex 
F 
M 
M 
M 
M 
M 
M 
M 
F 
F 
F 
M 
F 
F 
M 
F 
M 
atopic 
+ 
-
+ 
+ 
-
+ 
+ 
+ 
+ 
+ 
-
+ 
+ 
+ 
-
+ 
+ 
FEV, 
(%pred) 
71.0 
93.2 
90.0 
101.5 
96.0 
78.7 
54.2 
59.5 
83.5 
60.9 
100.0 
92.8 
101.6 
69.1 
60.5 
97.2 
57.3 
80.4 
4.2 
PDMUNDW 
(ml) 
1.3 
20.8 
1.5 
5.3 
2.4 
1.8 
0.9 
1.6 
2.1 
1.8 
1.9 
1.7 
4.5 
7.8 
1.2 
5.0 
2.8 
2.3 
0.5 
medication 
(*) 
s, с 
s ,b 
s,b 
s, b 
s ,b 
s,b 
s, b 
s, b 
s, b 
s, b 
s 
s 
s, bs 
s 
s
r
b 
s 
s .b 
(*) s: salbutamol, b: beclomethasone, c: cromoglycale, bs: budesonide. 
Twelve patients used inhaled corticosteroids, one patient cromolyn sodium and all subjects 
inhaled salbutamol regularly. The long-term reproducibility, with an interval of 2 to 3 
months, was investigated in 16 atopic asthmatics, group В (Table 4.2). 
Study design. All subjects performed an UNDW provocation test on 2 
different days, at the same time of the day, with at least one day in between. The baseline 
FEV, on those days was within 10% variation. All medication was stopped for a period of 
more than eight hours before each test. 
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Table 4.2: 
patient 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
15. 
16. 
mean 
SE 
patients charucteristict, group B. 
age sex 
(У) 
25 M 
39 F 
23 F 
22 M 
27 M 
37 F 
31 M 
37 M 
50 F 
26 M 
31 F 
26 M 
20 F 
38 F 
16 M 
25 M 
29.5 
2.2 
atopic 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
FEV, 
(%pred) 
41.8 
104.6 
86.6 
114.2 
88.5 
95.6 
73.9 
69.7 
92.6 
100.6 
77.5 
93.0 
97.9 
89.8 
64.9 
81.6 
85.9 
4.4 
PDJìist 
(μπιοί) 
0.01 
0.05 
0.002 
0.14 
0.16 
0.03 
0.17 
0.07 
0.04 
0.24 
0.002 
0.09 
0.004 
0.12 
0.04 
0.4 
0.10 
0.03 
PDjJJNDW 
(ml) 
0.6 
1.4 
0.6 
3.5 
2.0 
0.7 
3.4 
5.5 
2.4 
3.9 
0.4 
3.6 
0.5 
8.2 
1.0 
1.0 
2.4 
0.6 
UNDW provocation test. The UNDW provocation test was performed as 
described in paragraph 4.1. A dose-response curve was constructed on a semi-logarithmic 
scale. To assess the threshold and shape of the dose-response we calculated the PD^UN-
DW ', the area under the dose-response curve (AUC) ", the sensitivity 8 and the reactivity 
5
 (figures 4.3 and 4.4). 
Lung fimction. Maximal expiratory flow-volume curves were recorded using 
the pneumoscreen II (Jaeger, Würzburg, FRG). 
Statistical analysis. The reproducibility of the UNDW provocation test was 
calculated by a standard deviation (SD) for repeated measurements 1<,. Multiple compari-
son was performed by the Wilcoxon signed rank test with Bonferroni correction. 
Correlations were calculated by the Spearman-rank test. All data were presented as means 
+, standard error (SE). Significance was accepted for ρ < 0.05. 
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Results 
The baseline FEV, values on the days of measurement were not significantly 
different. The short-term reproducibility study was performed with a mean interval of 
12.8 ±_ 2.4 days, the long-term reproducibility was performed with a mean interval of 
94.9 +. 9.4 days. The mean values for PD^UNDW, AUC, sensitivity and reactivity on 
the two study days, their correlation and SD for repeated measurements are presented in 
table 4.3. All parameters, except for reactivity, showed a good short-term and long-term 
reproducibility on the two study days. The PDaUNDW values obtained during the short-
term study were within one doubling dose, during the long-term study only ne exceeded 
this range (figure 4.5). Correlations between the different thresholds, i.e. PDJBUNDW, 
AUC, sensitivity and reactivity values are presented in table 4.4. The PDBUNDW, AUC 
and sensitivity correlated well, whereas there was no correlation between these parameters 
and reactivity. 
Discussion 
The asthmatic subjects in this study were known to react to inhalation of 
UNDW. The PDjoUNDW, the sensitivity of the dose-response curve and the AUC 
correlated well, which indicates that these parameters represent a common characteristic 
of the dose-response curve. The PDXUNDW and the sensitivity showed a somewhat lower 
SD value for repeated measurements than the AUC. The reactivity .however, was not 
reproducible, 
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Table 4.3: Short-term and long-term reproducibility if parameters derived ßrom the UNDW dose-response 
curve in asthmatic patients. 
Short-term reproducibility (n=17) 
Spearman 
day 1 day 2 correlation SDg,, 
3.8±1.2 4.0±1.1 r=0.78 32.3% 
ρ < 0.005 
32.4±10.1 30.5±7.3 r=0.76 59.5% 
ρ < 0.005 
-8.0.+ 1.Э -8.1±1.3 r=0.82 43.9% 
ρ < 0.005 
-31.3±3.1 -27.4+.3.6 r=0.42 54.0% 
NS 
Long-term reproducibility (n=16) 
Spearman 
day 1 day 2 correlation SD^u 
2.4±0.6 2.7+.0.6 r=0.92 36.9% 
p<0.001 
23.8+6.7 24.5+.5.6 r=0.89 55.7% 
ρ < 0.005 
-12.7±3.2 -12.2±3.1 r=0.89 31.6% 
p<0.005 
-80.9±52.9 -38.8±5.6 r=0.12 
NS 
PDJOUNDW: the cumulative dose of inhaled UNDW causing a 20% fall in FEV,; 
AUC: area under the dose-response curve; 
S: sensitivity of the dose-response curve; 
R: reactivity of the dose-response curve; 
SDut,: standard deviation for repeated measurements. 
in contrast to the reactivity measured during histamine challenge " and it seems to be of 
no value, therefore, in assessing bronchial hyperresponsiveness to UNDW. The SD for 
PD^UNDW 
(ml) 
AUC 
S 
R 
PD^UNDW 
(ml) 
AUC 
S 
R 
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Table 4.4: Correlations between the PD^UNDW, area under the curve, sensitivity and reactivity values of 
the UNDW dose-response curve in asthmatic subjects. 
AUG 
Short-term 
interval 
PD.UNDW 
(ml) 
r=0.92 
p<0.001 
r=0.95 
p<0.001 
r=0.1 
p>0.5 
AUG r=0.81 
p<0.005 
r=-0.2 
p>0.4 
Long-term 
interval 
r=-0.2 
p>0.4 
PD^UNDW 
(ml) 
r=0.97 
p>0.00] 
r=0.99 
p<0.001 
r=-0.2 
p>0.4 
AUG r=0.93 
ρ < 0.005 
r=-0.3 
p>0.25 
r=-0.2 
p>0.5 
The presented values are the mean values of day 1 and day 2. PD^UNDW: the cumulative dose of inhaled 
UNDW causing a 20% fall in FEV,; 
AUC: area under the dose-response curve; 
S: sensitivity of the dose-response curve; 
R: reactivity of the dose-response curve; 
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repeated measurements of the PD^UNDW was 32.3% for short-term reproducibility and 
36.9% for long-term reproducibility. 
These results are comparable with reported and recalculated data on reproducibility for 
the UNDW provocation tests ,л г. From data in literature we calculated SD values for 
repeated measurements of 23.8% 12 and 43.0% " for the short-term reproducibility. The 
SD for long-term reproducibility, determined in 12 patients, was 30% when the test was 
repeated within six months '. With regard to the PD^UNDW, our data are comparable, 
therefore, with those reported in literature. The SD for repeated measurements of the 
PDJiistamine, as presented in chapter 2, revealed 10.4% for short-term reproducibility. 
As discussed in chapter 1, there is a clear difference in the mechanisms underlying 
bronchial hyperresponsiveness to histamine and UNDW. Histamine acts mainly directly 
on the airway smooth muscle, whereas UNDW inhalation a more complete pathway 
including mediator release in the airway wall u ' , s. This difference in underlying mecha­
nism may explain the smaller SD for histamine challenge. 
In conclusion, there is a good short-term and long-term reproducibility of 
the UNDW-induced bronchoconstnctor response in asthma, as measured with the 
PDaUNDW, AUG and sensitivity. The PDjoUNDW and the sensitivity showed the least 
variation with regard to the SD for repeated measurements. In the further studies 
presented in this thesis we have therefore chosen the PD^UNDW as threshold value to 
express changes in bronchial hyperresponsiveness to UNDW. 
4.4 DURATION OF UNDW-INDUCED BRONCHOCONSTRIC-
TOR EFFECT 
Introduction 
Few data are available on the time course of the UNDW-induced broncho­
constnctor response 7. It is unknown whether these results can be applied to all methods 
of UNDW challenge. Therefore, we investigated the duration of the bronchoconstrictor 
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effect induced by inhaling increasing doses of air with UNDW, as described in paragraph 
4.1. 
Patients and methods 
The duration of the bronchoconstriction after inhalation of the threshold dose 
of distilled water was investigated in 12 asthmatic subjects (Table 4.2, patient nos. 5-16). 
Their mean age was 30.8 +. 2.5 years with a mean baseline FEV, of 89.7 +, 3.6% of 
predicted; all patients were atopic. 
UNDW provocation test. The UNDW provocation test was performed as 
described in paragraph 4.1. 
Lung fimction. Maximal expiratory flow-volume curves were recorded with 
a pneumoscreen II (Jaeger, Würzburg, FRG). The duration of bronchoconstriction after 
reaching a 20% fall in FEV, was measured at 30, 90, 180 and 300 seconds after inhaling 
the last dose. 
100 
> 
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Figure 4.6: Duration of the bronctwconstrictor effect in 12 asthmatic patients after inhalation of the 
threshold dose of UNDW, causing a 20% fall in FEV¡, expressed as mean (+SE). There is a plateau of 
bronchoconstriction between 30 and 180 seconds after inhalation of the threshold dose. 
*p<0.01 versus 90 and 180 seconds. 
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Statistical analysis. Multiple comparison was performed by means of the 
Wilcoxon test with Bonferroni correction on all data. The FEV, was expressed as 
percentage calculated from baseline values. Data were presented as means +. standard 
error (SE). Significance was accepted for ρ < 0.05. 
Results 
The duration of bronchoconstriction after inhaling the UNDW threshold 
dose, i.e. the PDMUNDW, is shown in figure 4.6. 
The mean FEV, values 30, 90, 180 and 300 seconds after inhalation of the threshold dose 
were 79.6 +. 3.0, 78.5 ± 2.0, 78.6 ± 1.3 and 86.3 ± 1.9 % respectively, calculated of 
the post-air FEV, values. The mean FEV, values 30, 90, and 180 seconds after inhalation 
of PDa)UNDW-dose were not significantly different (p>0.5). At 300 seconds after 
UNDW inhalation the mean FEV, was significantly higher than the FEV, values at 90 and 
180 seconds (p=0.0076 and p=0.003 respectively). 
Discussion 
The bronchoconstriction induced by inhalation of UNDW, as measured with 
the FEV,, showed a plateau between 30 and 180 seconds after inhalation. Five minutes 
after inhalation the bronchoconstriction decreased. Our findings are in contrast with those 
of Allegra et al 7, who investigated the time course of UNDW-induced bronchoconstricti­
on in 13 asthmatic subjects. They found a 300% increase in specific airway resistance 
above baseline 5, 10 and 15 minutes after inhalation of distilled water compared to saline 
inhalation, although they did not measure airway conductance between 0.5 and 5 minutes 
after inhalation. These differences in duration of UNDW-induced bronchoconstriction 
could be due to differences in method of provocation. Allegra et al. ' challenged the 
patients with the inhalation of one dose of distilled water, i.e. 10 ml. In our protocol the 
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subjects inhaled doubling volumes of air with UNDW, starting with a dose of 3 liters of 
air with UNDW, which is equivalent to 0.2 - 0.5 ml H20, until a 20% fall in FEV, had 
been achieved. Thus, the inhaled dose of UNDW in our method is more adjusted to the 
specific, individual hyperresponsiveness, whereas in the method of Allegra et al. 7 one 
large volume of UNDW was inhaled, which may cause a more prolonged bronchocon­
striction. 
We conclude that after inhaling the threshold dose of UNDW a plateau of 
sustained bronchoconstriction is present between 30 and 180 seconds after inhalation of 
this dose. This implies that a 5-minute interval between the inhalation of two consecutive 
doses is long enough to measure the deepest fall in FEV,. 
4.5 UNDW- VERSUS fflSTAMINE-INDUCED BRONCHOCON­
STRICTION 
Introduction 
The histamine provocation test is a standardized method for the assessment 
of bronchial hyperresponsiveness and it is the most frequently used bronchial provocation 
test in clinical and research lung function laboratories 1б·'7. UNDW-induced bronchocon­
striction can also be used to measure bronchial hyperresponsiveness 7,'. In this study we 
investigated whether the histamine-induced bronchoconstrictor response is correlated to 
the UNDW-response as assessed with our method of challenging. 
Patients and methods 
The relation between the UNDW provocation test and the histamine 
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challenge was investigated in 16 atopic asthmatic patients (Table 4.2) Their mean age was 
29.5 ± 2.2 years and the mean baseline FEV, 85.9 ± 4.4% of predicted. The histamine-
and UNDW-challenges were performed on 2 different days, at the same time of the day 
and with an interval of at least one day in between. The baseline FEV, on those days was 
within 10% varation. All medication was stopped for a period of more than eight hours 
before each test. 
UNDW provocation test. The UNDW provocation test was performed as 
described in paragraph 4.1. 
Histamine provocation test. The histamine provocation test was performed 
according to Ryan et al ". The patients inhaled doubling doses of histamine administered 
with a dosimeter (Jaeger, Würzburg, FRG). The PD^histamine, the dose of inhaled 
histamine causing a 20% fall in FEV, from baseline values, was calculated in /xmol 
histamine from a semi-logarithmic dose-response curve by linear interpolation. 
Statistical analysis. Correlations were calculated by the least squares method 
after log.otransformation of the PDS data and expressed as Pearson coefficients. All data 
are presented as means +. standard error (SE) and lung function values are expressed as 
percentage of predicted ". Significance was accepted for ρ < 0.05. 
Results 
The baseline FEV, values on the days of measurement were not significantly 
different. The mean interval between the histamine and UNDW challenge was 3.3 +. 0.5 
days. The PDahistamine was 0.10 ± 0.03 дтоі and the mean PD^UNDW was 2.4 ± 
0.6 ml. A significant correlation existed between the log transformed PDJiistamine and 
PDJOUNDW values (r=0.72, p=0.002), as shown in figure 4.7. There was no correlation 
between the baseline FEV, and the PDJiistamine or PDjoUNDW. 
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Figure 4.7: Correlation between the VNDW- and histamine-induced bronchoconstrictor response in 16 
asthnuaic subjects, expressed as the PD-^UNDW and the PD-Jiistamine. The r-value indicates the Pearson 
coefficient of correiation of the PD
x
-values. 
Discussion 
In our patients the UNDW provocation test was significantly correlated to 
the histamine provocation test. Several other investigators have also compared the UNDW 
provocation test with histamine or methacholine provocation tests, as discussed in 
paragraph 3.3. In asthmatic children no correlation could be found between the fall in 
FEV, induced by inhalation of methacholine and UNDW "•21. In children, who seem to be 
less susceptible to UNDW bronchoconstriction 2I"D, the relationship between responsive-
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ness to distilled water and methacholine is probably not comparable with that in adults. In 
adults other authors have found significant correlations between methacholine- and 
UNDW- challenge 6·24·25 or histamine and UNDW *. 
We conclude that in adult asthmatic patients bronchial hyperresponsiveness 
to UNDW and histamine are significantly correlated, although the underlying mechanisms 
of the bronchoconstnction induced by physical and pharmacological stimuli appear to be 
different. 
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REFRACTORINESS FOR ULTRASONICALLY 
NEBULIZED DISTILLED WATER AND HISTAMINE 
AFTER HISTAMINE CHALLENGE 
C. Groot, J-W. Lammers, J. Festen and C. van Herwaarden. 
Journal of Applied Physiology 1991; 70: 1011-15. 
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5.1 ABSTRACT 
Refractoriness for bronchial provocation frequently occurs after different 
challenge tests used to assess bronchial hyperresponsiveness in asthmatic patients. We 
investigated whether histamine inhalation could cause refractoriness for bronchoconstricti-
on induced by ultrasonically nebulized distilled water (UNDW) and whether histamine 
causes tachyphylaxis for a subsequent histamine challenge in nine stable asthmatic 
patients. Preinhalation of histamine induced a significant diminished bronchoconstrictor 
response to UNDW cumulative dose of inhaled UNDW causing a 20% fall in forced 
expired volume in 1 s. The mean increased from 3.5 ± 0.8 ml to 11.8 +. 2.6 (SE) ml 
after histamine challenge (p < 0.01). However, repeated inhalation of histamine did not 
change the bronchoconstrictor response to histamine within 1 h after rechallenge (p > 
0.5). The magnitude of refractoriness for UNDW inhalation after preinhalation of 
histamine was correlated to the bronchoconstrictor response to histamine (r = 0.73, ρ < 
0.05). We conclude that inhaled histamine can induce refractoriness for UNDW, which 
seems to be related to the degree of bronchial hyperresponsiveness. 
5.2 INTRODUCTION 
Nonspecific bronchial hyperresponsiveness is an important feature of asthma. 
Pharmacological stimuli like histamine and methacholine ' and physical stimuli like 
exercise 2 and ultrasonically nebulized aerosols 3 are frequently used to measure the 
degree of bronchial hyperresponsiveness in the individual patient and to investigate the 
underlying mechanisms. Certain asthmatic patients responding to one of these stimuli 
demonstrate a substantial attenuated response after reexposure to the same stimulus within 
several hours after the first challenge. This phenomenon, known as tachyphylaxis in 
farmacological stimuli and refractoriness in physical stimuli, has been demonstrated in 
most provocation tests M . The underlying mechanisms are still not clear. 
The purpose of this study was to investigate whether refractoriness for ultrasoni-
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cally nebulized distilled water after preinhalation of histamine occurs and whether this 
phenomenon is correlated to tachyphylaxis for repeated inhalation of histamine in 
asthmatic patients. 
5.3 PATIENTS AND METHODS 
Subjects. (Table 5.1) Nine stable asthmatic patients participated in the study. 
Their mean age was 32.3 i 3.4 (SE) year and their mean baseline FEV, was 83.2 +. 5.7 
% of predicted '. Six patients had positive skin tests to common inhalational allergens. All 
patients were nonsmokers and had no respiratory infection within one month before the 
study. All patients were treated with inhaled albuterol, and four of them also used 
beclomethasone. The study protocol was approved by the Ethics Committee of the 
hospital and all patients gave informed consent before entry into the study. 
Table 5.1: Patient diaracteristia 
patient sex age FEV, atopic PD^iist medication 
(y) (%pred) (μ 8)(·) ( · · ) 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
M 
M 
M 
F 
F 
F 
M 
F 
F 
50 
41 
35 
21 
26 
24 
25 
39 
30 
60.5 
57.7 
80.7 
100.6 
75.2 
84.5 
91.9 
95 9 
101.6 
-
-
+ 
+ 
+ 
+ 
+ 
-
+ 
7.7 
29.3 
44.1 
76.5 
94.1 
99.9 
279.0 
454.5 
545.9 
s. b 
s, b 
s.b 
s, b 
s 
s 
s 
s 
s 
mean 32.2 83.6 171.4 
SE 3.4 5.7 65.0 
(*) PD^Hist: The dose of inhaled histamine causing a 20% fall 
ш FEV,; 1 μg histamine = 0.0033 μ mol. 
(**) s: salbutamol, b: beclomethasone dipropnonate 
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Study Design. Each subject was studied on 4 different days with an interval 
of at least one day. All medication was stopped 8 hours before each test. On days 1 and 
3, UNDW provocation tests were performed. On day 2, a histamine provocation test was 
followed by an UNDW test when the FEV, had returned spontaneously to within 10% of 
the baseline values. On day 4, a histamine provocation test was followed by a second 
histamine provocation test when the FEV, had again returned spontaneously within 10% 
of the baseline values. 
UNDW provocation test. The UNDW test was performed according to 
Anderson et al 3. An ultrasonic nebulizer (Ultraneb 99, DeVilbiss, Somerset, PA) was 
used at a fixed output of 2.00 +. 0.10 ml/min. The patient inhaled the aerosol at tidal 
breathing through a mouthpiece with tightened lips and the nose clipped. A two-way valve 
(Leardal IV, Stavanger) was placed between the aerosol hose and the mouthpiece. A 
Wright respirometer (British Oxygen, London, UK) was attached to the two-way valve to 
measure the total volume of inhaled air. The patient started with inhaling 20 liters of 
ambient air through the system. Thereafter, 3, 5, 10, 20, 40, 80, and 160 liters of air 
with UNDW were successively inhaled at 5-min intervals. Lung function was measured 
by recording flow-volume curves obtained with a pneumoscreen (model II, Jaeger, 
Wurzburg, FRG) at 30, 90, and 120 s after inhalation of each dose. The test was stopped 
when a 20% fall in FEV, was achieved or when the last dose of air with UNDW.i.e. 160 
liters, was inhaled. Before and after each test, the nebulizer chamber and aerosol hose 
were weighed. A log dose-response curve was constructed, and the cumulative dose of 
inhaled distilled water (in ml H20) causing a 20% fall in FEV, compared with the lowest 
post-air FEV, (PD^UNDW) was calculated by linear interpolation. 
Histamine provocation test. The histamine provocation test was performed 
according to Ryan et al 10. The patient inhaled doubling doses of histamine, increasing 
from 1.35 |ig to 720 Mg, administered with a dosimeter (Jaeger, Wurzburg, FRG). The 
PDjohistamine, the dose of inhaled histamine causing a 20% fall in FEV,, was calculated 
in micrograms by linear interpolation. The total dose of histamine inhaled was also 
calculated. 
Statistical analysis. The PDaUNDW values obtained at day 1 and 3 were 
averaged for comparison with the PD^UNDW values after prior inhalation of histamine. 
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The PDJiistamine data of day 2 and 4 were also averaged for comparison with the 
second PD^histamine on day 4. Before statistical analysis a natural log transformation of 
PDjpUNDW and PDjohistamine values was performed. An analysis of variance for 
repeated measurements was performed on data where a student-t test for correlated 
samples was not appropriate. Correlations were calculated with the Spearman rank 
method on non-log transformed data. All data are presented as means +. SE and statistical 
significance was accepted at ρ < 0.05 for all tests. 
5.4 RESULTS 
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Figure 5.1: Reproducibility of the UNDW tests. The PDJUNDWs on day 1 and day 3 (PDJUNDW (1) and 
PDJUNDW (2), respectively) were within 1 doubling dose. 
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The baseline FEV, before each test on the 4 study days was within 10% 
variation with mean values ranging from 2.99 ± 0.27 L to 3.08 ± 0.33 L. The reprodu­
cibility of PDJOUNDW on day 1 and 3 is shown in figure 5.1. The differences between 
each PDJJUNDW on day 1 and 3 were within one doubling dose and the mean PD. 
»UNDW's on those two days were not significantly different. Figure 5.2 shows the log 
dose-response curves of the ultrasonically nebulized distilled water provocation tests for 
all subjects individually. 
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Figure 5.2: Log dose response curves of UNDW provocation tests in 9 asthmmatic patients. • .· UNDW 
provocation test on day 1, *: UNDW provocation test on day 3, *: UNDW after prior inhalation of 
histamine on day 2 
There was no significant difference between between the distilled water provocation tests 
on day 1 and 3, with mean PDj, values of 3.3 ± 0.8 and 3.7 ± 1.0 ml H20, respective­
ly. Three of nine patients (patients 5, 7 and 8) did not reach a 20% fall in FEV, after 
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inhalation of the last dose of distilled water after pre-inhalation of histamine. They 
inhaled 20 ml of distilled water cumulatively. In all subjects the UNDW and histamine 
challenge after pre-inhalation of histamine were performed within one hour after the end 
of the baseline histamine inhalation test. After preinhalation of histamine the mean 
PDaUNDW significantly increased to 11.8 ± 2.6 ml H20 (p < 0.01), as shown in figure 
5.3a. The increase in mean PD^UNDW was 1.5 +, 0.3 doubling dose. 
15 -i 
ε io -
Q 
Ζ 
3 
Q 
a. 
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ρ < 0.01 
UNDW 1 UNDW 2 UNDW 
after histamine 
Figure 5.3a: Mean PD^UNDW bifore (UNDW 1 and UNDW 2) and after histamine challenge. A significant 
increase in mean PD^UNDW (p < 0.01) was induced by preinhalation of histamine. 
The PDjnhistamine measured on day 2 and 4 were identical, with mean values of 171.4 +. 
65.0 ßg and 172.9 +. 62.7 Mg, respectively. After preinhalation of histamine on day 4 a 
mean PD^histamine of 205.8 +. 86.6 μξ was measured for the second challenge, which 
value was not significantly different from the baseline PDJiistamine values obtained at 
day 2 and 4 (Figure 5.3b). 
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Figure 5.3b: Mean baseline FDJùstamine values measured on two study days (Hist 1 and Hist 2) and the 
mean PDJiistamine obtained after histamine challenge. There is no significant difference in mean 
PDJiistamine values (p > 0.5). 
The difference between the baseline PDjoUNDW measured on day 1 and 3 
and the PD^UNDW after pre-inhalation of histamine was calculated and called the shift in 
PDaUNDW. A significant correlation was found between the shift in PD^UNDW and the 
baseline PD^histamine (r= 0.73, p= 0.036). Also, the last dose of histamine inhaled, 
before the UNDW test after preinhalation of histamine was started on day 2, was 
correlated to the change in PDaUNDW (r= 0.72, p=0.04). No correlation was found 
between the change in PD^UNDW and the total dose of histamine inhaled. 
5.5 DISCUSSION 
In this study we have demonstrated that preinhalation of histamine before 
inhalation of UNDW causes refractoriness for UNDW-induced bronchoconstriction in a 
82 
Chapters 
group of mildly asthmatic patients. However, prior inhalation of histamine did not change 
the bronchoconstnctor effect of a second histamine challenge within one hour on the same 
day. 
Refractoriness to the bronchoconstnctor effect of the same stimulus has been 
shown for exercise ', inhalation of hypertonic and hypotonic aerosols 3·5, and inhalation of 
adenosine 5'monophosphate 6. Refractoriness after hyperventilation-induced bronchocon-
striction has not clearly been demonstrated ". Tachyphylaxis has been reported to occur 
after repeated inhalation of histamine in asthmatic subjects *·12. 
The underlying mechanism of refractoriness is still unknown. Cromoglycate, 
a mast-cell-stabilizing agent, can inhibit UNDW-induced bronchoconstriction 3. Significant 
neutrophil chemotactic activity levels in blood have been found after UNDW provocation 
". Also, leukotrienes D4 and E4 seems to be involved because pretreatment with an 
antagonist of these mediators diminished UNDW-induced bronchoconstriction 14. Depleti­
on of bronchoconstrictor mediators from mast cells has been suggested to have a role in 
the refractoriness for repetitive UNDW provocation 3. In histamine provocation, pretreat­
ment with cromoglycate could not prevent bronchoconstriction IS, so mast-cell-derived 
mediators seem to have no important role in the histamine-induced bronchoconstrictor 
response. Therefor mast cell depletion seems to be unlikely to be the cause in histamine-
induced refractoriness for UNDW. 
Bronchodilating cyclooxygenase products like prostaglandin Ег seem to have 
an important role in refractoriness and tachyphylaxis *•". Pretreatment with indomethacin 
inhibited both refractoriness for repeated inhalation of UNDW and tachyphylaxis for 
repeated inhalation of histamine e · ' 6. Blockade of the H2-receptors with Cimetidin, a 
specific H2-receptor antagonist, inhibited tachyphylaxis for repeated inhalation of 
histamine ". Jackson et al. ", therefore postulated that Hj-receptors modulate prostaglan­
din release after histamine challenge and that these receptors seems to be involved in 
tachyphylaxis. Prostaglandin release due to histamine provocation probably has some 
inhibiting effects on mediator release in UNDW challenge. 
We also investigated whether in asthmatic patients a correlation can excist 
between the total amount of histamine inhaled and the magnitude of refractoriness for 
UNDW after preinhalation of histamine. No such correlation was found, but we did find 
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a significant correlation the last dose of inhaled histamine and the shift in PD^UNDW. A 
significant correlation was also found between the PD^histamine and the shift in PDjoUN-
DW after preinhalation of histamine. These correlations suggest that the magnitude of 
refractorines is not determined by the total amount of inhaled histamine, but that the 
severity of the bronchial hyperresponsiveness appears to be more important. Thus patients 
with severe bronchial hyperresponsiveness to histamine are less susceptable for refractori-
ness for UNDW-induced bronchoconstriction than asthmatic subjects with a lower degree 
of bronchial hyperresponsiveness. 
Repeated inhalations of histamine did not cause a significant shift in 
PDjohistamine. Although there was a small rise in mean PD^histamine after preinhalation 
of histamine the shift did not reach significance. These results comfirm those of Ruffin et 
al. ", who also could not demonstrate a difference in PCJiistamine after repeated 
inhalation of histamine. Even four successive histamine provocation tests on one day 
could not induce tachyphylaxis in their group of asthmatic patients. Schoeffel et al. " 
were also not able to induce tachyphylaxis with three succesive inhalation challenges with 
histamine, although these autors did not calculate changes in PD^histamine. Kung et al. * 
could also not demonstrate changes in PDJiistamine after consecutive histamine challen-
ges. These data and the results of our study are in contrast with those of Jackson et al " 
and Connolly et al 12, who showed significant tachyphylaxis for histamine after repeated 
inhalation in their groups of patients, although the shift in mean PC^histamine " and 
mean PD^histamine '2 were within one doubling dose. The time between the first test and 
the rechallenge was the same for all these studies, 30 - 90 min. 
An explanation for the differences between these studies may be a difference 
in patients selection. Ruffin et al. " investigated subjects with mild to moderate asthma, 
with a mean PCjohistamine of 2.78 mg/ml (range: 0.3 - 5.3 mg/ml), and only one of their 
12 patients was atopic. Jackson et al. " investigated a group of mild atopic asthmatics, 
mean PCjohistamine 3.01 mg/ml (range: 1.5 - 5.0 mg/ml). Our group was a mixed 
population of mild to moderate asthmatics with a mean PDJiistamine values of 171.9 ßg 
(3.83 mg/ml, range: 0.15 - 11.1 mg/ml) and 6 patients were atopic. Connelly et al.12 
investigated a group of 20 patients and 18 were atopic, and Kung et al.20 investigated a 
group of asymptomatic asthmatics and did not differentiate between atopic and nonatopic 
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patients. The PD^histamine used in the last two studies 1Sili was calculated as the 
cumulative dose of inhaled histamine, and therefore can not be compared with the values 
mentioned above. 
Mild stable asthma which does not require inhaled corticosteroids, has been 
suggested to be a discriminating aspect for the occurence of tachyphylaxis for histamine 8. 
However, in a group of asymptomatic patients " who did not use any medication, 
tachyphylaxis could not be demonstrated. Thus there is no clear difference between the 
study groups which can explain the differences in outcome other than the atopic status; 
however, distinction between atopic and nonatopic only with skintests seems to be of less 
importance 21 and is limited to the panel of inhalation allergens used. 
We conclude that preinhalation of histamine causes refractoriness for 
inhalation of UNDW in asthmatic patients. The magnitude of this refractoriness seems to 
be inversely correlated to the severity of bronchial hyperresponsiveness to histamine. 
Tachyphylaxis for histamine could not be demonstrated in these patients. 
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THE PROTECTIVE EFFECTS OF IPRATROPIUM 
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Chapter 6 
6.1 ABSTRACT 
UNDW-induced bronchoconstriction can be inhibited by fl2-agonists, drugs with 
mast cell stabilizing properties like cromoglycate, and anticholinergic drugs like atropine. 
The dose related protective effects of ipratropium bromide in UNDW challenge are not 
clear. 
In a randomized, double-blind, placebo-controlled study, we investigated the pro-
tective effects of ipratropium bromide 160 Mg and 320 Mg and terbutaline 500 Mg on 
UNDW-induced bronchoconstriction in nine stable asthmatic patients. To compare the 
drug effects, we determined the PD^UNDW and the reactivity and sensitivity of the 
UNDW dose-response curve. Both drugs caused a significant increase (p<0.001) in 
baseline FEV, with no significant differences between the drugs or both doses of 
ipratropium bromide. Pre-inhalation of ipratropium bromide 320 Mg and terbutaline 500 
Mg inhibited UNDW-induced bronchoconstriction as measured by PD^UNDW and sensi-
tivity (p<0.01), whereas ipratropium bromide 160 Mg had no protective effect. There 
was no correlation between the increase in baseline FEV, and PDjoUNDW indicating that 
the protective effect on UNDW-induced bronchoconstriction is not dependent on the 
bronchodilatation induced by terbutaline and ipratropium bromide. It also appears that the 
UNDW-induced bronchoconstriction is at least partly vagally mediated. 
6.2 INTRODUCTION 
Bronchial hyperresponsiveness is a major characteristic feature of bronchial 
asthma1. Inhalation of ultrasonically nebulized distilled water (UNDW) can induce 
bronchoconstriction in asthmatic subjects and has been used for assessment of bronchial 
hyperresponsiveness2. The underlying mechanism of UNDW-induced bronchoconstriction 
has not been elucidated yet. 
Acknowledgement: We kindly thank Astra Pharmaceutics and Boehringer Ingelheim for providing the test 
medication. 
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Рге-inhalation of sodium cromoglycate2 and nedocromil sodium3 can inhibit UNDW-
induced bronchoconstriction, indicating that mast cell-derived mediators probably are 
involved. Furthermore, the cholinergic nervous system seems to be involved, since pre-
inhalation of atropine can prevent UNDW-induced bronchoconstriction4. The protective 
effects of the non-selective muscarine receptor antagonist 
ipratropium bromide on UNDW-induced bronchoconstriction is not clear yet. Doses used 
in general practice, i.e. 40 ßg and 80 ßg, did not show any protection56. e2-agonists, like 
salbutamol5 and fenoteroron the contrary can totally block the UNDW-induced broncho-
constrictor response. 
Therefore, the aim of this study was to investigate the effect of ipratropium 
bromide on UNDW-induced bronchoconstriction. We used two different doses of 
ipratropium bromide to assess whether its effect is dose-dependent and we compared the 
effects of ipratropium bromide with those of placebo and the ßj-agonist terbutaline. 
6.3 PATIENTS AND METHODS 
Table 6.1: palian diaracteristia 
patient 
1 
2 
3 
4 
5 
6 
7 
8 
9 
mean 
SE 
sex 
F 
F 
M 
M 
F 
F 
M 
F 
M 
age 
(У) 
24 
33 
53 
50 
22 
44 
37 
43 
16 
38.9 
FEV, 
(% pred.) 
90.9 
118.3 
56.8 
61.4 
73.9 
84.3 
54.1 
108.9 
92.5 
82.3 
4.3 
PDshist 
(μπίοΐ) 
0.20 
0.18 
0.03 
od 
0.01 
0.23 
0.002 
0.23 
0.05 
0.12 
0.04 
PD^UNDW 
(ml) 
6.5 
1.4 
1.3 
2.0 
5.3 
8.1 
1.3 
4.0 
3.0 
3.6 
0.8 
medication 
С) 
a, b 
a,b 
a . b 
a, b 
a 
a 
a, b, ¡b 
a, b 
a, b 
(*) a: salbutamol, b: beclomethasone, ib: ipratropium bromide, nd: not done 
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Subjects. Nine stable asthmatic subjects participated in the study, their 
characteristics are given in table 6.1. 
All patients, except for patient no. 9, were non-allergic with respect to history and 
negative reactions to intracutaneous skin tests. Inhalation of a ß^-agonist induced an in-
crease in FEV, of more than 15% and all patients reacted to inhalation of UNDW before 
the start of the trial with at least a 20% decrease in FEV,. Anti-asthmatic medication was 
stopped for a period of 8 hours before each test, but inhaled corticosteroids were 
continued without changing the dose during the study. None of the patients had used 
systemic corticosteroids for a period of at least three months or suffered from a respirato-
ry tract infection for a period of at least one month before the start of the study. The 
study was approved by the local Ethics Committee and all patients gave their written 
informed consent. 
Study design. The patients attended the lung function laboratory on four 
different days at the same time of the day with intervals of at least one day. The baseline 
FEV, on those days had to be within 10% variation. After recording baseline flow-volume 
curves (Pneumoscreen Π, Jaeger, Würzburg, FRG) the subjects inhaled double-blind and 
in a randomized order: placebo, ipratropium bromide 160 μg, ipratropium bromide 320 
Mg or terbutaline 500 μ%. Ipratropium bromide was inhaled by means of a metered dose 
inhaler, 20 μ% per puff, through a 750 ml spacer device and terbutaline was inhaled as a 
powder by means of a turbuhaler00 (Astra, Lund, Sweden), 500 Mg per inhalation. Thirty 
minutes after inhalation of the test drugs an UNDW provocation test was performed. 
Measurements. Flow-volume curves were recorded to measure lung function 
before and during the UNDW provocation tests. 
UNDW provocation tests were performed with the Ultraneb 99 ultrasonic nebulizer 
(DeVilbiss, Somerset, USA), according to a modified method described in paragraph 4.1. 
The PDJOUNDW, the cumulative dose of UNDW causing a 20% fall in FEV,, was calcu­
lated from post-air values by linear interpolation on a semi-logarithmic curve and 
expressed in ml НзО". If a 20 % fall in FEV, was not achieved, the PD^UNDW was 
equated to the total amount of inhaled UNDW. 
To assess the effect of ipratropium bromide and terbutaline on the dose-response curve, 
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the sensitivity, the slope of a linear regression line of the total dose-reponse curve' and 
reactivity, the slope of a linear regression line of the steepest part of the curve10, were 
calculated, as shown in figure 6.1. 
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Figure 6.1: A dose-response curve, that of patient nr.8, with on the X-axL· the amount cf inhaled VNDW, 
and on the Y-axL· the FEV¡ as percentage of the post-air value. The broken line represents the dose-response 
curve. Slope A, the linear regression of the toted curve, expresses the sensitivity and slope B, a linear 
regression of the steepest part of the curve, expresses the reactivity. 
Statistical Analysis. The FEV, is expressed as percentage of predicted". The 
increase in FEV,, 30 minutes after inhalation of the drugs, is expressed as percentage of 
the baseline FEV,. The changes in PD^UNDW are expressed in doubling doses calculated 
from placebo values. All data were analyzed by the Wilcoxon test and multiple compari-
son was performed with the Bonferroni correction. Correlations were calculated by the 
Spearman-rank test. All data are presented as means with standard error (+. SE). Sta-
tistical significance was accepted for ρ < 0.05. 
6.4 RESULTS 
The baseline FEV, values on the 4 study days were not significantly 
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different (p=0.6). The increase in FEV, versus the increase in PD^UNDW, expressed in 
doubling doses, both calculated from baseline values is shown in figure 6.2. 
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Figure 6.2: A scattergram representing the increase in FEV, versus the increase in PD^UNDW, calculated 
from baseline values, after inhaled ipratropium bromide 160 μg (panel A), ipratropium bromide 320 μg 
(panel B) and terbutaline (panel C). 
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Figure 6.3: The changes in UNDW-induced bronchoconstriction expressed as PD^UNDW after preinhalation 
of placebo (PL), ipatropium bromide 160 pg (IBía¡ VJ and 320 μg (IBm μ ι ) , and terbutaline 500 ßg (I). 
Solid lines indicate individual changes in PD-JUNDW. The broken line represents the mean changes in 
PD^UNDW (± SE). 
Table 6.2: Effects cf placebo, ipratropium bromide 160 μ ; and 320 μ£ and terbutaline 500 ßg on the mean 
values (± SE) of PD^UNDW (expressed in ml H fi), and reactivity and sensitivity of the UNDW dose-
response curves (both expressed in arbitrary units). 
PDXUNDW REACmm SENSlTIVnr CORRELATION 
(slopej (slopej PDm-slopeA PD^-slopeg 
Placebo 
Ipratropium 
Bromide 160 ßg 
Ipratropium 
Bromide 320 ßg 
terbutaline 
500 ßg 
3.6± 0.8 -40.7 + 10.0 -7.3 + 1.9 
6.5 + 2.2 -29.8 + 4.9 -5.0 + 1.3 
NS 
NS 
14.5 + 3.0** -22.5+5.6 -2.0 + 0.7*4 NS 
16.4 + 3.1*4 -18.6 + 6.1 -1.6 + 0.6*4 NS 
r,=0.99 
ρ=0.005 
r. =0.98 
p=0.006 
r,=0.98 
p=0.006 
r.=0.95 
p=0.007 
* : ρ < 0.005 versus placebo 
4 : p< 0.0125 versus ipratropium bromide 160 ßg 
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The mean baseline FEV,, increased from 79.1 ± 6.9% to 80.9 ± 8.3 % after placebo 
(p=0.45), from 79.9 ± 7.2 % to 92.7 ± 6.5 % after ipratropium bromide 160 ßg 
(p=0.008), from 82.8 ± 7.0 % to 95.5 ± 6.0 % after ipratropium bromide 320 Mg 
(p=0.008) and from 79.6 ± 7.5 to 91.8 ± 7.8 % after terbutaline (p=0.008). The two 
doses of ipratropium bromide as well as terbutaline induced a similar, more than 15% 
increase in baseline FEV,. 
The individual and mean changes in PDXUNDW are shown in table 6.2 and figure 6.3. 
Ipratropium bromide 160 ßg improved the PDJBUNDW 0.6 +. 0.3 doubling dose, which 
was not significantly different from placebo (p=0.17). Ipratropium bromide 320 Mg and 
terbutaline provided a significant protection against UNDW-induced bronchoconstriction 
compared to placebo and increased the PD^UNDW 1.9 +, 0.4 and 2.1 ± 0.4 doubling 
dose respectively (p=0.002). This protection was significantly better than that of ipratro-
pium bromide 160 ßg (p=0.01), but there was no significant difference in protection 
between ipratropium bromide 320 ßg and terbutaline 500 ßg (p=0.38). Terbutaline 
caused a total inhibition of the UNDW-induced bronchoconstrictor response in 3 patients, 
with a mean fall in FEV, of 2.9 +. 1.5 %, whereas ipratropium bromide 320 /ig comple-
tely inhibited the UNDW response in 2 patients. No significant correlation was found 
between the increases in FEV, 30 minutes after inhalation and the changes in PD^UNDW 
induced by the drugs studied. 
The reactivity of the dose-response curves was not significantly changed by 
inhalation of the test drugs in comparison with placebo (p=0.43), as shown in table 6.2. 
The sensitivity of the dose-response curves, was not significantly different after pre-
treatment with ipratropium bromide 160 ßg compared to placebo (p=0.13). Ipratropium 
bromide 320 ßg and terbutaline induced a significant change in sensitivity of the dose-res-
ponse curve compared to placebo (p=0.003) and ipratropium bromide 160 ßg (p=0.006). 
There was no significant difference between the sensitivity of the UNDW dose-respons 
curves after the inhalation of ipratropium bromide 320 ßg or terbutaline (p=0.68). The 
sensitivity of the dose-response curve was strongly correlated to the PD^UNDW values 
(table 6.2). There were no significant correlations between the PDjo values and the reac-
tivitie of the UNDW dose-response curves. 
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6.5 DISCUSSION 
In this study we have demonstrated that pre-inhalation of ipratropium bromide 320 
μ% or terbutaline 500 μ% can inhibit UNDW-induced bronchoconstriction in asthmatic 
patients, although the bronchoconstrictor response was not totally blocked in all patients. 
The bronchodilatation induced by the study drugs was not maximal for all patients as 
shown by the mean FEV, 30 minutes after inhalation, ranging from 91.8 to 95.5 % of the 
predicted values. Preinhalation of ipratropium bromide 160 Mg increased the baseline 
FEV, significantly and to the same degree as ipratropium bromide 320 Mg and terbutaline 
500 Mg. However, ipratropium bromide 160Mg did not inhibit UNDW-induced broncho­
constriction as measured by the PD^UNDW and the sensitivity of the dose-response 
curve. 
We did not find a correlation between the increase in FEV, and the degree of 
protection as illustrated in figure 6.2, which indicates that the protective effect was not 
solely due to the bronchodilator response of the drugs. This means that the protective 
effect of ipratropium bromide is related to the amount of inhaled drug. These findings are 
supported by the results of other studies 5·'2. Doses of 80 Mg inhaled ipratropium bromide 
had no protective effect, whereas doses above 200 Mg induced a significant protection 
against UNDW-induced bronchoconstriction. The mechanism of the inhibition by ipra­
tropium bromide of the UNDW-induced bronchoconstriction in asthmatics is not known. 
In contrast to ß2-agonists, ipratropium bromide has no stabilizing effects on mast cell 
degranulation as shown during allergen provocation". Decreased airway smooth muscle 
supersensitivity14 or an inhibition of a vagal reflex induced by ipratropium bromide", 
might be the mode of action of this drug. Since the protective effect of muscarinic 
receptor antagonists to bronchoconstrictor stimuli only appears to be mediated through the 
inhibition of acetylcholine release'*, our results support the idea that bronchoconstriction 
induced by UNDW in asthmatics is at least partially mediated by a vagal reflex mecha-
nism. 
Our data show a large individual variation in the protective effect of ipratropium 
bromide 320 Mg on UNDW-induced bronchoconstriction. This finding is confirmed by 
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Ihre et al.", who found a remarkable interindividual variation in bronchodilation and 
protection for histamine-induced bronchoconstnction due to ipratropium bromide, whereas 
they found only a small intraindividual varation. 
The protective effect of terbutaline was not complete in all subjects. This was not 
what we had expected from literature, since ß2-agonists like salbutamol totally blocked 
UNDW-induced bronchoconstnction5. Terbutaline 500 /ig, however, showed significantly 
less protection in histamine-induced bronchonstriction than fenoterol 400 μg and salbuta­
mol 200 Mg", which may support our findings. 
Intraindividually the PDaUNDW is a well reproducible threshold when dose-
response curves are compared8. However, there may be some limitations of this threshold 
in dose-response curves where a 20% fall in FEV, after challenge is not achieved, as 
occurred in some patients in this study after pretreatment with a bronchodilator. For these 
patients the PD^UNDW was equated to the total amount of inhaled UNDW. Moreover, 
this threshold gives no information about the shape of the dose-response curve. We 
therefore calculated the reactivity and sensitivity of the individual dose-response curves 
after placebo and both study drugs, which as far as we know, has not been done before 
for the UNDW-induced bronchoconstrictor response. The sensitivity was strongly 
correlated with the PD^UNDW and the changes in the sensitivity of the dose-response 
curves induced by ipratropium bromide and terbutaline were comparable to those in 
PDJOUNDW. The reactivity, however, showed no significant change after prior broncho-
dilatation, although the data seem to indicate a trend towards a less steep slope after 
inhalation of the bronchodilator drugs. The large standard error due to the large interin­
dividual variation of the reactivity in this small group of patients, may add to non 
significant changes and shows the limitation of this parameter. 
We conclude that in comparison with a regular dose of terbutaline only a high 
dose of inhaled ipratropium bromide provides significant protection against UNDW-
induced bronchoconstnction. This inhibition is not solely related to the bronchodilator 
effect of ipratropium, but is probably also due to blockade of a vagally mediated reflex 
induced by UNDW. 
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7.1 ABSTRACT 
In a randomized crossover study we compared the effects of inhaled nedocromil 
sodium, 4 mg q.i.d., with inhaled beclomethasone dipropionate, 200 μg q.i.d. in 23 
atopic asthmatic patients. After a 3-week single-blind placebo period, regarded as the 
baseline, and after 4 and 8 weeks of active treatment, drug effects were assessed with 
regard to bronchial hyperresponsiveness to histamine and distilled water, lung function, 
and ß2-agonist use. After 4 and 8 weeks of treatment, nedocromil sodium decreased the 
histamine responsiveness (p<0.005 and p<0.0005), but not the distilled water responsi-
veness, and did not improve lung function and peak flow measurements compared to the 
baseline. After 4 and 8 weeks of treatment, beclomethasone caused a significant increase 
in lung function (p< 0.005) and decrease in bronchial hyperresponsiveness to histamine 
(p< 0.0005) and distilled water (p< 0.0005) as compared to the baseline, ßj-agonist use 
was significantly diminished after an 8-week treatment with beclomethasone, whereas 
nedocromil sodium had no effect. Treatment with beclomethasone was superior to 
treatment with nedocromil sodium with regard to bronchial hyperresponsiveness to 
histamine and distilled water (p< 0.0005 and ρ < 0.005), lung function (p=0.003), 
peakplow measurements (p<0.05) and ß2-agonist use (p< 0.005). 
7.2 INTRODUCTION 
Bronchial hyperresponsiveness to a variety of chemical, physical and pharmacolo-
gical stimuli is one of the major characteristics of bronchial asthma 'Λ The underlying 
mechanism of bronchial hyperresponsiveness is still unknown, but several aspects have 
been elucidated recently. Disruption of the epithelial layer, inflammatory changes in the 
airway wall and possibly an imbalance in the autonomic regulation of the airway appear 
to contribute to the pathophysiology of bronchial hyperresponsiveness '•\ 
The presence and the degree of bronchial hyperresponsiveness can be assessed by 
bronchoprovocation tests with pharmacological and physical stimuli. Hargreave et al. * 
found a correlation between the severity of asthma and the degree of bronchial hyperres-
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ponsiveness to histamine and methacholine. Non-specific stimuli like exercise 5 and 
ultrasonically nebulized distilled water (UNDW) ' can also be used for the assessment of 
bronchial hyperresponsiveness. The latter challenges are supposed to have the advantage 
of corresponding better with the daily exposure of the asthmatic subject to non-specific 
stimuli7. 
The treatment of asthma is focussed on diminishing the inflammatory process and 
the bronchial hyperresponsiveness '. In a previous study we compared the effects of 
sodium cromoglycate and budesonide on bronchial hyperresponsiveness in asthmatic 
subjects '. Budesonide induced a significant decrease in bronchial hyperresponsiveness to 
histamine and exercise, whereas sodium cromoglycate did not have such effects. Nedocro­
mil sodium, a pyranoquinoline dicarboxylic acid derivative, has anti-inflammatory 
properties, as demonstrated by in vitro and in vivo experiments, and seems to be more 
potent than sodium cromoglycate u,. Nedocromil sodium can inhibit early- and late-phase 
asthmatic responses after allergen inhalation ", and prevents bronchoconstriction induced 
by inhaled SO2 '2, cold air l3, distilled water '\ substance Ρ '5, adenosine ", and exercise 
". However, the place of this drug in the treatment of asthma has not been defined yet. 
The aim of the present study was to investigate the effects of regularly inhaled nedocromil 
sodium in comparison with inhaled beclomethasone diproprionate on lung function, 
bronchial hyperresponsiveness to histamine and distilled water, and ßj-agonist use in 
allergic asthmatic subjects. 
7.3 PATIENTS AND METHODS 
Subjects. Twenty-eight non-smoking subjects with allergic bronchial asthma " 
participated in the study. All patients were recruited from the hospital outpatient depart-
ment. Some characteristics of these patients are shown in table 7.1. 
Allergy was defined as two or more positive intracutaneous skin test reactions to common 
airborne allergens. Patients with seasonal allergy did not participate in the study during 
that specific season. The pre-challenge forced expiratory volume in one second (FEV,) 
had to be > 50% of the predicted values " and reversibility of FEV, had to be > 15% in 
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TabU 7.1: 
patient 
1 
2 
3 
4 
5 
б 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
mean 
SE 
Patient characteristics. 
sex 
F 
F 
F 
M 
M 
F 
F 
M 
M 
F 
M 
M 
F 
M 
F 
M 
F 
M 
F 
F 
M 
M 
M 
F 
M 
M 
M 
M 
age 
(y) 
40 
35 
27 
26 
22 
23 
38 
25 
26 
40 
26 
21 
44 
38 
32 
17 
19 
28 
38 
21 
31 
19 
27 
50 
38 
21 
17 
30 
29.3 
1.7 
FEV, 
(%pre<l) 
100 
85 
68 
89 
95 
87 
82 
51 
89 
72 
101 
63 
99 
66 
74 
87 
91 
89 
98 
100 
71 
78 
107 
93 
65 
82 
70 
103 
84.1 
2.7 
MEF, 
(%pred) 
72 
49 
34 
74 
110 
75 
37 
23 
53 
50 
73 
31 
76 
36 
56 
55 
68 
52 
99 
58 
38 
46 
93 
66 
34 
50 
40 
59 
57.3 
4.0 
M E F B 
(%pred) 
78 
41 
39 
64 
155 
53 
37 
23 
61 
62 
63 
18 
66 
33 
64 
51 
46 
57 
83 
54 
42 
40 
81 
77 
34 
41 
39 
48 
55.3 
4.9 
hist 
(μιηοΙ) 
0.05 
0.05 
0.50 
0.40 
0.24 
0.09 
0.12 
0.002 
0.09 
0.19 
0.24 
0.002 
0.01 
0.24 
0.002 
0.03 
0.17 
0.16 
0.03 
0.004 
0.17 
0.002 
0.09 
0.04 
0.04 
0.06 
0.04 
0.24 
0.12 
0.02 
P D , 
UNDW 
(ml) 
1.4 
1.0 
13.7 
0.9 
10.7 
0.6 
8.2 
0.6 
3.6 
5.3 
6.2 
0.1 
1.7 
4.3 
0.4 
9.8 
2.4 
2.0 
0.7 
0.5 
3.4 
0.3 
-
2.4 
5.5 
1.6 
1.0 
3.5 
3.4 
0.7 
previous 
medication 
s, b 
s, b 
s 
s, b 
s 
s, b 
s.b 
s, с 
s, b 
s,b 
s,b 
s, bud 
s,b 
s, bud 
s, b 
s.b 
s, bud 
s, bud 
s, b 
s, b 
s, bud 
s.b 
s 
s,b 
s, b 
s,b 
s,b 
s 
FEV, : forced expiratory volume in one second; MEF,, and MEF^ : maximal expiratory flow when 50% 
and 25% of the forced vital capacity have to be expired; s = salbutamol powder inhalation; с = 
cromoglycate powder inhalation; b = beclomethasone powder inhalation; bud = budesonide aerosol. 
response to an inhaled ß2-agonist. 
The PDJiistamine, the dose of histamine causing a 20% fall in FEV, from pre-challenge 
values, was below 0.59 μπιοί ( <4 mg/ml) inhaled histamine for all subjects. None of 
the patients had used systemic corticosteroids for a period of six months or had suffered 
from had a respiratory tract infection for a period of one month before the start of the 
study. Twenty-three patients used inhaled corticosteroids before entering the study with an 
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average dose of 400 μg twice a day to control their asthma. All previous medication was 
stopped when the patients entered the first placebo period. 
The study was approved by the local Ethics Committee and all patients gave their written 
informed consent. 
Study Design. The study was carried out according to a randomized crossover 
and double-dummy design (figure 7.1). A three-week single-blind wash-out placebo 
period was followed by two periods of double-blind active treatment, each lasting eight 
weeks, and separated by a second single-blind wash-out placebo period of three weeks. 
The placebo periods were regarded as the baseline before the active treatment periods. 
During the active treatment periods the patients inhaled nedocromil sodium, 4 mg q.i.d. 
(Fisons Ltd., Loughborough, UK) or beclomethasone dipropionate, 200 μ% q.i.d. (Glaxo 
Ltd., The Netherlands) from a metered dose inhaler. During the study patients were 
allowed to inhale salbutamol from a metered dose inhaler as rescue medication. No other 
anti-asthma drugs were allowed during the trial. 
PLACEBO PLACEBO 
wash-out waah-out 
BECLOMETHASONE 
NEDOCROMIL 
3 wk 8 wk 3 wk 8 wk 
lung function 
t t | | | | histamine 
UNDW 
t I | f diary card 
Figure 7.1: Study design of the double-blind, randomized crossover comparison of nedocromil sodium and 
beclomethasone in atopic asthmatic patients. 
X 
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Measurements. At the end of both placebo periods and after 4 and 8 weeks of 
active treatment, a histamine provocation test and an ultrasonically nebulized distilled 
water (UNDW) provocation test were performed on two different days with at least one 
day in between to avoid histamine-induced tachyphylaxis for UNDW-induced bronchocon-
striction ". The variation in the pre-challenge FEV, on these two days had to be within 10 
%. Salbutamol was withheld for a period of at least 8 hours before each test and the trial 
medication was stopped for a period of at least 24 hours to avoid any direct drug effects 
on the provocation tests. 
Lung Function. Flow-volume curves were performed to measure lung function 
(Pneumoscreen II, Jaeger, Würzburg, FRG) before and during each provocation test. The 
mean of the FEV! values before the UNDW and histamine provocation tests in each 
period was regarded as the pre-challenge FEV,. 
Histamine provocation tests were performed according to Ryan et al. а . The 
patients inhaled doubling doses of histamine (0.03 - 16 mg/ml) from a dosimeter (Jaeger, 
Würzburg, FRG). Six maximal inspirations were used to deliver 45 μΐ of histamine per 
dose. Inhalation of a concentration of 45 μί of 1 mg/ml resulted in a dose of 0.15 μπιοΐ. 
Flow-volume curves were recorded at 30, 90 and 180 seconds after inhalation. The 
PDjohistamine was calculated from pre-challenge values by linear interpolation on a semi-
logarithmic curve. 
UNDW provocation tests were performed with the Ultraneb 99 ultrasonic 
nebulizer (DeVilbiss, Sommerset, USA), according to a modified method described by 
Anderson et al. ". 
The output was fixed at 2 ml/min, which output was measured when the equipment was 
not attached. Air with UNDW was inhaled through a mouthpiece with tightened lips and 
nose clipped. A Leardal IV 2-way valve (Stavanger, Norway), with a dead space of 24 
ml, was placed between the aerosol hose and the mouthpiece. A respirometer (British 
Oxygen Company, London, UK) was connected to the expiratory port of the two-way 
valve to measure the total volume of inhaled air. After inhalation of 20 liters of ambient 
air through the system, doubling volumes of air with UNDW (3, 5, 10, 20, 40, 80 and 
160 liters) were inhaled at 5-minute intervals. Flow-volume curves were recorded 30, 90 
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and 180 seconds after inhalation. The test 
was stopped when the last dose of air with UNDW, i.e. 160 1, was inhaled or a 20% fall 
in FEV, was achieved. Before and after each test the nebulizer chamber and aerosol hose 
were weighed and the total amount of inhaled UNDW was measured in ml H20. The 
PDJOUNDW, the cumulative dose of inhaled distilled water in ml H20 causing a 20% fall 
in FEV, from post-air values, was calculated by linear interpolation on a semi-logarithmic 
curve. 
Diary cards. Morning and evening peakflow measurements were recorded with a 
mini-Wright peakflow meter, the best of three attempts, and daily use of bronchodilators 
was registered as the total number of inhalations of salbutamol during the last 2 weeks of 
the placebo and the active treatment periods. 
Statistical Analysis. PD^histamine and PD^UNDW data, FEV, values, and data 
obtained from diary cards were analyzed by the Wilcoxon signed rank test. For multiple 
comparisons a Bonferroni correction was used. The shift in PDa, values was calculated as 
the difference between the real baseline values and the values after 4 and 8 weeks of 
treatment. The changes in PDjo values were also expressed as doubling doses of inhaled 
histamine and UNDW, calculated from the individual baseline values. Period effects and 
carry-over effects were analyzed according to Pocock n by the Mann-Whitney U test. 
Correlations were calculated by the Spearman-rank test. FEV, values are presented as 
percentage of predicted ". Data are presented as mean +_ standard error (SE) and 
statistical significance was accepted for ρ < 0.05. 
7.4 RESULTS 
The study was completed by 23 patients. Five patients (nrs.2,10,16,17 and 28) 
were unable to come to the laboratory for lung function and provocation tests at the 
appointed intervals and withdrew from the study voluntarily during the first active 
treatment period. Patient nrs. 2, 16, 17 and 28 had started with beclomethasone and nr. 
10 had started with nedocromil sodium. None of the patients failed to complete the study 
due to an exacerbation of their asthma or the need of additional medication. One patient 
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Table 7.2: Carry-over and period effects of the two adive treatment periods. 
group I(·) group Π(·) carry-over 
effect 
period 
effect 
Geometric mean Geometric mean 
PDJiistamine (цпюі) 
(η-11) (ιι=12) 
BDP 
baseline 
8 wks 
NS 
baseline 
8 wks 
FD„UNDW (ml) 
BDP 
baseline 
8 wks 
NS 
baseline 
8 wks 
FEV, {% pred.) 
BDP 
baseline 
8 wks 
NS 
baseline 
8 wks 
ß2-agonist use 
(puffs/day) 
BDP 
baseline 
8 wks 
NS 
baseline 
8 wks 
0.02 
0.30 
0.03 
0.12 
0.9 
4.1 
1.7 
1.8 
79 
91 
82 
86 
(n=8) 
2.3 
2.0 
3.6 
5.5 
0.07 
0.44 
0.06 
0.15 
1.7 
6.4 
2.0 
1.0 
81 
89 
82 
85 
(n=ll 
5.5 
2.5 
3.2 
4.5 
p=0.49 p=0.67 
p=0.38 p=0.32 
p=0.36 p=0.81 
p=0.29 p=0.15 
(*) Group I represents the patients who started with beclomethasone, group II represents the patients who 
started with nedocromil sodium. The data are expressed as geometric means. 
no 
Chapter 7 
Table 7.3: FEV¡ and PDX values, peaiflow rate in the morning and the evening, andßj-agonist use during 
baseline and after 4 and 8 weeks qf treatment. 
fcçlpmrthaSQng 
FEV, 
(% predicted) 
PDJiis tamme 
(μπιοί) 
PD.UNDW 
(ml) 
peakflow (l\min) 
(monuog) 
(evening) 
Bj-agonist use 
(puffs/day) 
nedocromil sodium 
FEV, 
(% predicted) 
PDJiistamine 
(μπιοί) 
PD,UNDW 
(ml) 
peakflow (l/min) 
(morning) 
(evening) 
ßragonist use 
(puffs/day) 
baseline 
79.8 ±3.7 
0.04 ±0.03 
1.3 ± 0 . 6 
459 ± 2 3 
470 ± 2 2 
3.3 ±0.8 
82.4 ±3.7 
0.05 ±0.04 
1.9 ±0 .7 
468 ± 2 4 
489 ± 2 2 
3.4 ±0 .8 
4wk 
treatment 
89.6 ± 3 . 4 · * 
0.28±0.13***** 
5.3 ± 2 . 2 * · · * 
86.4 ±3 .0 
0.10 ± 0 . 0 3 · · 
2.7 ±1 .5 
8wk 
treatment 
89.5 ± 3 . 0 · · * 
0 . 3 7 ± 0 . 1 8 · · · * Ο 
6.2 ± 2 . 5 · · · * * 
494 ± 2 6 · * 
505 ± 2 5 * 4 
2.2 ± 0 . 5 · · 4 * 
84.8 ± 3 . 3 
0.13 ± 0 . 0 7 · · · 
1.8 ± 2 . 0 
471 ± 2 3 
492 ± 2 3 
4.9 ± 0 . 8 
data are presented as geometric mean ± SE; * = p<0.05, ** = p<0.005 and **+ = p<0.0005 versus 
the baseline; • = p<0.05, •• = p<0.005 and ••• = p<0.0005 versus nedocronul sodium. 
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(nr 23) did not react to UNDW. The diary cards of 18 patients could be evaluated for 
peakflow measurements and ßj-agonist use. 
Of the 23 patients who completed the study, 11 patients started with beclometha-
sone and 12 with nedocromil sodium during the first active drug period. There were no 
period or carry-over effects for all parameters as shown in table 7.2. 
None of the parameters, i.e FEV, values, PDjohistamine, PD^UNDW, ßj-agonist 
use and peakflow measurements were significantly different in the two baseline periods 
(table 7.3). 
Treatment with beclomethasone induced a significant improvement of the mean FEV, and 
decreased bronchial hyperresponsiveness to histamine and UNDW (table 7.3 and figure 
7.2) after 4 and 8 weeks of treatment as compared to the baseline values. 
Nedocromil sodium decreased bronchial hyperresponsiveness to histamine, but not to 
UNDW after 4 and 8 weeks of treatment and did not improve FEV, as compared to the 
baseline values during placebo treatment. 
Treatment with beclomethasone was significantly better for all parameters, except for the 
baseline FEV, after 4 weeks of treatment. 
The changes in PDJiistamine and PD^UNDW, expressed as doubling doses, are 
presented in table 7.4. There was no significant difference in doubling doses between 
histamine and distilled water. 
Table 7.4: Changes in PDJiistamine and PD^UNDW calculated from baseline values and expressed as 
doubling doses. 
4 wk 8 wk 
treatment treatment 
beclomethasone 
PDahistamine 
PDaUNDW 
nedocromil sodium 
PDjjhistamine 
PDaUNDW 
2.5 ± 0.4· 
1.8+0.3*· 
1.2 + 0.3 
0.7 ± 0.2 
2.9 ± 0.4· 
2.3 ± 0.4·· 
1.4 ± 0 . 3 
0.8 + 0.3 
data are presented as mean ±_ SE, * = p<0.05, and * · = p<0.01 and versus nedocromil sodium 
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Figure 7.2: Geometrie means (± SE) of the PDJustamine (panel A) and PD^UNDW (panel B) during 
baseline and afler 4 and 8 weeks of treatment with beclomethasone (open bars) and nedocromil sodium 
(shaded bars). 
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A significant correlation was found between PDJiistamine and PD^UNDW during 
placebo (^=0.76) and after 8 weeks of treatment with beclomethasone (r.=0.73) and 
nedocromil sodium (r.=0.87)(p<0.005 for the three periods). The shift in PDJiistamine 
and PDJDUNDW after 4 weeks of treatment with beclomethasone showed no correlation, 
whereas after 8 weeks of treatment a significant correlation (r,=0.64, p=0.004) was 
found. There were no correlations between the PD» values for histamine and UNDW and 
the FEV,. 
Both morning and evening peakflow rates were significantly increased and ß2-
agonist use was significantly decreased after 8 weeks of treatment with beclomethasone 
compared to the baseline values and treatment with nedocromil sodium (table 7.3 and 
figure 7.3) 
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Figure 7.3: Geometrie means (+_ SE) of the ^-agonist use during the ¡ast week of the baseline period and 
beclomethasone (open bars) and nedocromil sodium treatment (shaded bars). 
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7.5 DISCUSSION 
The results of our study demonstrate that, in patients with allergic asthma, 
treatment with inhaled beclomethasone in a total daily dose of 800 Mg improves lung 
function and decreases bronchial hyperresponsiveness to histamine and distilled water 
provocation, after 4 and 8 weeks of treatment. Beclomethasone also reduces the need for 
additional bronchodilators as reflected by a decrease in daily use of salbutamol. Nedocro-
mil sodium with a total daily dose of 16 mg decreases bronchial hyperresponsiveness to 
histamine, but not to UNDW, after 4 and 8 weeks of treatment. Nedocromil sodium had 
no effect on lung function and ß2-agonist use either. Bronchial hyperresponsiveness and 
most lung function parameters were significantly better during treatment with beclometha-
sone than with nedocromil sodium. 
Our results are partly comparable with those of a study in non-allergic patients 
with mild asthma ^, comparing a total daily dose of 400 Mg beclomethasone with 16 mg 
nedocromil sodium. The authors measured a significant decrease in bronchial hyperres-
ponsiveness to methacholine after 4 and 8 weeks of treatment with beclomethasone and 
after 8 weeks of treatment with nedocromil sodium. Only beclomethasone could induce a 
significant increase in lung function, but no significant diffences were found between 
beclomethasone and nedocromil sodium Ώ. 
In the present study beclomethasone induced a significant increase in both 
morning and evening peakflow rates, whereas nedocromil sodium had no significant 
effects. These findings are in contrast with those of a study comparing beclomethasone 
400 Mg daily with nedocromil sodium 16 mg daily in a group of 13 asthmatic subjects u. 
This study showed that after 8 weeks of treatment with both beclomethasone and 
nedocromil sodium there were significant increases in morning and evening peakflow 
rates. ß2-agonist use was lower during beclomethasone treatment, whereas nedocromil 
sodium had no significant effect. 
The significantly better effect of beclomethasone, compared to nedocromil 
sodium, on bronchial hyperresponsiveness, lung function, and flî-agonist use in our group 
of atopic asthmatic patients is probably related to the dose of beclomethasone used and the 
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characteristics of our patients with respect to their degree of airway hyperresponsiveness. 
Other studies ^23, who investigated a lower dose of beclomethasone, i.e. 400 μg daily, 
and an equal amount of nedocromil sodium, i.e. 16 mg, could not demonstrate significant 
differences between both treatments. A further difference between the these studies ^ 2 5 
and ours is the degree of bronchial hyperresponsiveness. Twenty-three of our patients 
used inhaled corticosteroids before entering the study, in contrast to a minority of the 
patients from the studies referred to а 2 5 . This may indicate more severe asthma in our 
group of patients. Nevertheless, nedocromil sodium in a total daily dose of 16 mg seems 
to be less potent in this group of patients. Comparing the duration of treatment needed to 
achieve significant effects on asthma, beclomethasone-induced changes can be demonstra­
ted after 3 to 4 weeks of treatment, whereas the effects of nedocromil treatment become 
clear after 4 to 8 weeks of treatment, as can be concluded from our data and the data 
from other studies ^23. During beclomethasone treatment the bronchial hyperresponsive­
ness to histamine further improved between 4 and 8 weeks of treatment, whereas this 
effect could not be demonstrated for nedocromil sodium. 
Beclomethasone treatment significantly improved both FEV, and bronchial 
hyperresponsiveness to histamine and UNDW. This may suggest that the improvement in 
bronchial hyperresponsiveness is partly the result of increase in lung function. Although a 
correlation between the degree of airway obstruction and bronchial hyperresponsivenss 
has been found in a heterogeneous population *, this correlation does not seem to exist in 
asthmatic subjects in contrast to patients with a chronic airway obstruction ". As for 
asthmatics, this is confirmed by our data, since we also could not demonstrate a correlati­
on between pre-challenge FEV, and the PDJiistamine or PDjoUNDW. Hence, in asthma 
the pre-challenge FEV, seems to be a relatively minor determinant for the improvement of 
bronchial hyperresponsiveness. 
PDjohistamine and PD^UNDW showed a good correlation during the trial. The 
shifts in PDjn values for histamine and UNDW were not significantly different. Therefore, 
it appears that histamine and UNDW are equally sensitive in detecting changes in 
bronchial hyperresponsiveness induced by anti-inflammatory drugs as beclomethasone in 
asthmatic patients. However, during beclomethasone treatment there was no correlation 
between the change in PDahistamine and PDjoUNDW after 4 weeks of treatment, whereas 
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after 8 weeks of treatment a significant correlation was found. Furthermore, the increase 
in PDjohistamine was significantly more pronounced after 8 weeks than after 4 weeks of 
treatment with beclomethasone. This indicates that beclomethasone-induced effects in 
asthma are probably measured by histamine and UNDW challenge on a different level of 
bronchial responsiveness. These findings are supported by what we know about the 
underlying mechanisms in histamine- and UNDW-induced bronchoconstriction, which are 
not identical. The histamine bronchoconstrictor response is mainly a direct effect of the 
drug on the airway smooth muscles ', whereas in UNDW-induced bronchoconstriction 
also the release of mediators from inflammatory cells, like mast cells, seems to be 
involved a . Preinhalation of sodium cromoglycate can totally block UNDW-induced 
bronchoconstiction and prevent mediator release 'u,, but it has no effect on histamine-
induced bronchoconstriction ", 
Nedocromil sodium also has an inhibitory effect on UNDW-induced bronchoconstriction 
when inhaled 30 minutes before the challenge N ·" . The duration of this protective effect in 
UNDW provocation is unknown. In exercise testing the protective effect of nedocromil 
sodium lasts at least 2 hours 17. We arbitrarily stopped beclomethasone and nedocromil 
sodium for a period of 24 hours before histamine and UNDW challenge to prevent a 
direct blocking effect on the bronchoprovocation tests. The lack of a significant change in 
PDaUNDW during nedocromil sodium indicates that after 24 hours the direct inhibitory 
effect, probably caused by a blockade of mediator release, has disappeared. The benefici-
al effects of beclomethasone was not influenced by the 24 hour withdrawal period. In 
contrast to the inhaled corticosteroids, nedocromil sodium in this dose appears to have no 
long-lasting effects on mediator release, as measured by UNDW-induced bronchoconstric-
tion. The sole effect of nedocromil sodium treatment in our study was a decrease in 
bronchial hyperresponsivenss to histamine. The mode of action of long-term effects of 
nedocromil sodium in asthmatic subjects is not known. This decrease in bronchial 
hyperresponsiveness to histamine probably indicate a reduction of the inflammation in the 
airway smooth muscles, although treatment with nedocromil sodium could not improve 
the other parameters. 
Topically administered corticosteriods have shown to reduce the number of mast cells in 
the skin and diminish the measurable histamine release dramatically ". In asthmatics, 
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corticosteroid treatment induces a significant fall in whole blood histamine, a mast cell 
mediator ". Thus, corticosteroids appear to deplete or reduce the stores of histamine in 
tissue 34'M and probably modify mediator release 3S. This may partly explain the difference 
of treatment effects of both drugs on UNDW-induced bronchoconstriction. 
We conclude that nedocromil sodium, 16 mg daily, has anti-asthmatic properties 
in this group of allergic asthmatic patients, as demonstrated by a significant decrease in 
bronchial hyperresponsiveness to histamine after 4 and 8 weeks of treatment. Beclometha-
sone, 800 μg daily, however, showed superior effects compared to nedocromil sodium 
with regard to the decrease in ß2-agonist use after 8 weeks of treatment, the increase in 
lung function after 4 and 8 weeks and the decrease of bronchial hyperresponsiveness 
measured by histamine and UNDW after 4 and 8 weeks of treatment. 
7.6 REFERENCES 
1. Holgate ST, Beasley R, Twentyman OP. The pathogenesis and significance of bronchial 
hyperresponsiveness in airway disease. Clin Science 1987; 73:561-572. 
2. Boushey HA, Holtzman MJ, Shcller JR, Nadel JA. Bronchial hyperreactivity. Am Rev 
Respir Dis 1980; 121:389^413. 
3. Hargreave FE, Ramsdale EH, Kirby JG, O'Byrne PM. Asthma and the role of inflammati-
on. Eur J Respir Dis 1986; 69(Suppl 147):16-21. 
4. Hargreave FE, Ryan G, Thomson NC, et al. Bronchial responsiveness to histamine and 
melhacholine in asthma: measurement and clinical significance. Eur J Respir Dis 1982; 
63(Suppl 121):79-88. 
5. Anderton RC, Cuff NIT, Frith PA, et al. Bronchial responsiveness to inhaled histamine and 
exercise. J Allergy Clin Immunol 1979; 63:315-320. 
6. Anderson SD, Schoeffel RE, Finney M. Evaluation of ultrasonically nebulized solutions for 
provocation testing in patients with asthma. Thorax 1983; 38:284-291. 
7. Pauwels R, Joos G, Straeten van der,M.. Bronchial hyperresponsiveness is not bronchial 
hyperresponsiveness is not bronchial asthma. Clin Allergy 1988; 18:317-321. 
8. Woolcock AJ, Yan K, Salome CM. Effect of therapy on bronchial hyperresponsiveness in 
the long-term management of asthma. Clin Allergy 1988; 18:165-176. 
9. Molema J, Herwaarden CLA,van, Folgering HThM. Effects of long-term treatment with 
inhaled cromoglycate and budesonide on bronchial hyperresponsiveness in patients with 
allergic asthma. Eur Respir J 1989; 2:308-316. 
10. Thomson NC. Nedocromil sodium: an overview. Respir Med 1989; 83:269-276. 
11. Abraham WM, Sielczak MW, Wanner A, et al. Cellular markers of inflammation in the 
airways of allergic sheep with and without allergen-induced late response. Am Rev Respir 
Dis 1988; 138:1565-1571. 
12. Jackson DM, Eady RP. Acute transient S02-induced airway hyperreactivity: effects of 
nedocromil sodium. J Appi Physiol 1988; 65:1119-1124. 
13. Juniper EF, Kline PA, Morris MM, Hargreave FE. Airway constriction by isocapnic 
118 
Chapter 7 
hyperventilation of cold, dry air: comparison of magnitude and duration of protection by 
nedocromil sodium and sodium cromoglycate. Clin Allergy 1987; 17:523-528. 
14. Robuschi M, Simone Ρ, Vaghi Ρ, Bianco S. Prevention of fog induced bronchoconstriction 
by nedocromil sodium. Eur J Respir Dis 1986; 69(Suppl 147):286-288. 
15. Crimi N, Palermo F, Oliven R, et al. Effects of nedocromil on bronchospasm induced by 
inhalation of substance Ρ in asthmatic subjects. Clin Allergy 1988; 18:375-382. 
16. Phillips GD, Scott VL, Richards R, Holgate ST. Effect of nedocromil sodium and sodium 
cromoglycate against bronchoconstriction induced by inhalation of adenosine 5'monophosp-
hate. Eur Respir J 1989; 2:210-217. 
17. König Ρ, Hordvik NL, Kreutz С. The preventive effect and duration of action of nedocromil 
sodium and cromolyn sodium on exercise-induced asthma in adults. J Allergy Clin Immunol 
1987; 79:64-68. 
18. American Thoracic Society . Standards for the diagnosis and care of patients with chronic 
obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987; 136:225-244. 
19. Quaryer PhH. Standardized lung function testing. Bull Eur Physiopathol Respir 1983; 
19(S5):3-95. 20. Groot С, Lammere J-W, Festen J, Herwaarden C.van. Refractoriness for 
ultrasonically nebulized distilled water and histamine after histamine challenge. J Appi 
Physiol 1991; 70:1011-1015. 
21. Ryan G, Dolovich MB, Obminski G, et al. Standardization of inhalation provocation tests: 
influence of nebulizer output, particle size, and method of inhalation. J Allergy Clin 
Immunol 1981; 67:156-161. 
22. Pocock SJ. Crossover trials. In: Clinical trials. Chishester: Wiley and sons, 1983; 110-122. 
23. Bel EH, Timmers MC, Hermans J, Dijkman JH, Sterk PJ. The long-term effects of 
nedocromil sodium and beclomethasone dipropionate on bronchial hyperresponsiveness to 
methacholine in nonatopic asthmatic subjects. Am Rev Respir Dis 1990; 141:21-28. 
24. Harper GD, Neill P, Vathenen AS, Cookson JB, Ebden P. A comparison of inhaled 
beclomethasone dipropionate and nedocromil sodium as additional therapy in asthma. Respir 
Med 1990; 84:463-469. 
25. Bergmann KCh, Bauer CP, Overlack A. A placebo-controlled comparison of nedocromil 
sodium and beclomethasone dipropionate in bronchial asthma. Lung 1990; SuppI:230-239. 
26. Cockcroft DW, Killian DN, Mellon JJA, Hargreave FE. Bronchial reactivity to inhaled 
histamine: a method and clinical survey. Clin Allergy 1977; 7:235-243. 
27. Ramsdale EH, Morris MM, Roberts RS, Hargreave FE. Bronchial responsiveness to 
metacholine in chronic bronchitis: relationship to airflow obstruction and cold air responsi­
veness. Thorax 1984; 39:912-918. 
28. Shaw RJ, Anderson SD, Durham SR, et al. Mediators of hypersensitivity and "fog"-induced 
asthma. Allergy 1985; 40:48-57. 
29. Moscato G, Rampulla С, Dellabianca A, Zanetti E, Candura S. Effect of salbutamol and 
inhaled sodium cromoglycate on the airway and neutrophil chemotactic activity in nfog"-in-
duced bronchospasm. J Allergy Clin Immunol 1988; 82:382-388. 
30. Patel KR. Sodium cromoglycate in histamine and melhacholine reactivity in asthma. Clin 
Allergy 1984; 14:143-145. 
31. del Bufalo С, Fasano L, Palalano F, Gunella G. Inhibition of fog-induced bronchoconstricti­
on by nedocromil sodium and sodium cromoglycate in intrinsic asthma: A double-blind, 
placebo controlled study. Respiration 1989; 55:181-185. 
32. Lavker RM, Scheeler NM, Robertson CR. Cutaneous mast cell depletion results from 
topical corticosteriod treatment. Clin Res 1984; 32:597A. (Abstract) 
33. Bruce C, Weatherstone R, Seaton R, Taylor WH. Histamine levels in plasma, blood and 
urinein severe asthma and the effect of corticosteriod treatment. Thorax 1976; 31:724. 
119 
Chapter 7 
34. Kaliner M. Mechanisms of glucocorticosteroid action in bronchial asthma. J Allergy Clin 
Immunol 1985; 76:321-329. 
35. Schleimer RP. Effects of glucocorticoids on inflammatory cells relevant to their therapeutic 
applications in asthma. Am Rev Respir Dis 1990; 141:s59-s69. 
120 
Chapter 7 
121 
Chapter 7 
122 
CHAPTERS 
CORRELATIONS OF SYMPTOM SCORES AND ß2-
AGONIST USE WITH BRONCHIAL 
HYPERRESPONSIVENESS TO HISTAMINE AND 
DISTILLED WATER AND PERCEPTION OF 
DYSPNOEA DURING HISTAMINE AND DISTILLED 
WATER CHALLENGE. 
C.A.R. Groot, J.-W.J. Lammers, J. Festen and C.L.A. van Herwaarden. 
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8.1 ABSTRACT 
We studied the correlations between asthma symptom scores, ß -^agonist use and 
bronchial hyperresponsiveness to histamine and distilled water, during a double-blind, 
crossover study comparing 8 weeks of treatment with beclomethasone to that of 
nedocromil sodium. Before each active treatment the patients used placebo, as wash-out, 
for a period of 3 weeks. Asthma symptom scores were evaluated in 18 allergic asthmatic 
subjects. Eight weeks of treatment with beclomethasone significantly decreased daytime 
dyspnoea (p=0.002) and ß2-agonist use (p=0.002) as compared to nedocromil sodium. 
Furthermore, asthma symptom scores were correlated to the bronchoconstrictor responses 
induced by inhalation of histamine and UNDW. The distilled water-induced 
bronchoconstrictor response correlated slightly better or more consistently to daytime 
dyspnoea and ß2-agonist use than to histamine-induced bronchoconstriction. Assessment of 
the change in dyspnoea during bronchial challenge demonstrated a significant correlation 
between the increase in dyspnoea and the fall in FEV, during distilled water inhalation, 
but not during inhalation of histamine. 
These results indicate that differences in pathophysiologic mechanisms underlying 
bronchial hyperresponsiveness to histamine and distilled water are reflected in their 
relationship to ß2-agonist use and asthma symptoms score registered on diary cards and 
during bronchial challenge. Distilled water-induced bronchoconstriction correlates slightly 
better and more consistently to asthma symptom scores and ß^-agonist use than histamine. 
8.2 INTRODUCTION 
Asthma symptom scores and bronchial hyperresponsiveness to non-specific 
stimuli indicate asthma severity '. However, assessment of asthma severity by recording 
symptom scores and questionnaires may not be a sensitive tool for discrimination between 
subjects with and without asthma or bronchial hyperresponsiveness to histamine and 
methacholine in epidemiologic surveys M. In asthmatic patients Brooks et al 5 found a 
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significant correlation between severity of complaints deduced from a specialised 
questionnaire and bronchial hyperresponsiveness to methacholine. In a previous study 
Molema et al.' investigated the correlations between asthma symptoms and bronchial 
hyperrresponsiveness to histamine and exercise during placebo and budesonide treatment. 
Only a consistent correlation between ß2-agonist use and PCahistamine could be 
demonstrated, whereas correlations to asthma symptoms were poor. Physical stimuli like 
inhaled distilled water have been suggested to correlate better with asthma symptoms 
because of their similarity to naturally occurring non-specific stimuli 7. As discussed in 
chapters 1 and 3 the pathophysiologic mechanisms underlying bronchial 
hyperresponsiveness to inhaled histamine and distilled water are different. Histamine and 
methacholine inhalation mainly induce bronchoconstriction through direct airway smooth 
muscle contraction and therefore assess reactivity and contractility of airway smooth 
muscle function 7. In UNDW-induced bronchoconstriction the release of inflammatory 
mediators and vagal reflexes are also involved. Thus, distilled water inhalation assesses a 
more complete pathway of bronchial hyperresponsiveness 7. The aim of this study was to 
investigate whether differences in underlying mechanisms of bronchial 
hyperresponsiveness to histamine and distilled water are reflected in differences in their 
relationship with asthma severity as measured by symptom scores, i.e. daytime dyspnoea, 
nighttime dyspnoea and ßj-agonist use. These tests were performed during long-term 
treatment with beclomethasone and nedocromil sodium in allergic asthmatic subjects. 
Furthermore, asthma symptoms were recorded during bronchial challenge with histamine 
and distilled water to investigate symptom perception during increasing 
bronchoconstriction. 
8.3 PATIENTS AND METHODS 
Subjects. Twenty-eight non-smoking asthmatic subjects 8, with a reversibility > 
15 % in response to an inhaled ßj-agonist, participated in the study which was a part of the 
study described in chapter 6. All patients were atopic, defined as two or more positive 
intracutanous skin test reactions to common airborne allergens. The study was approved 
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by the local Ethics Committee and all patients gave their written informed consent. 
Study Design. In a randomized crossover, double-blind, double-dummy study, 8 
weeks of treatment with nedocromil sodium, 4 mg q.i.d. (Fisons Ltd., Loughborough, 
UK) was compared to 8 weeks of treatment with beclomethasone diproprionate, 200 ßg 
q.i.d. (Glaxo Ltd, The Netherlands), both inhaled from a metered dose inhaler. 
A single-blind three-week placebo wash-out period was followed by two periods of active 
treatment, each lasting eight weeks, and which was separated by a second placebo wash-
out period of three weeks, as shown in figure 6.1. The placebo wash-out periods were 
concidered as baseline periods. Salbutamol was allowed as rescue medication. No other 
anti-asthma drugs were used during the study. 
At the end of both placebo periods and after 4 and 8 weeks of active treatment, a 
histamine provocation test ' and an UNDW provocation test '" were performed to assess 
bronchial hyperresponsiveness. Salbutamol was withheld for at least 8 hours before each 
test and the trial medication was stopped for at least 24 hours. 
To investigate the perception of dyspnoea during histamine and distilled water 
inhalation the patients recorded the severity of dyspnoea and coughing on a visual analog 
scale (VAS) ", with a length of 10 cm, five minutes before the bronchoprovocation tests 
and at the deepest fall in FEV, during the challenge. The increase in dyspnoea and 
coughing during the tests was calculated in cm from baseline values. The fall in FEV, 
during the tests was calculated in percentage fall from baseline values. 
Diary card. The patients recorded daytime and nighttime dyspnoea, coughing and 
ßj-agonist use on a diary card during the last two weeks of the placebo and active 
treatment periods. The symptom scores during the last week of each period were used 
for statistical analysis. The severity of dyspnoea symptoms during the day and during the 
night were registered on a visual analog scale (VAS) ". The daily use of bronchodilators 
was recorded by the patients as the total number of inhalations of salbutamol. 
Statistical Analysis. The diary card data and treatment effects were analyzed by 
the Wilcoxon test with Bonferroni correction. Correlations were calculated by the 
Spearman-rank test. Comparison of correlations were performed by comparing the 
involved cross-products by the Wilcoxon test. Baseline FEV, values were presented as 
percentage of predicted l2. All data are presented as mean +. SE and statistical 
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significance is accepted for ρ < 0.05. 
Table 8.1: Spearman correlation coefficients between daytime dyspnoea (D^, nighttime dyspnoea (ffj, ßj-
agonist use (ßj, PDJiistamine (PD^H) and the PDJUNDW (PD-JJ). 
BASELINE PERIOD 1 
ρο,,υ 
D D 
ND 
flj 
0.76" 
-0.36 
-0.28 
-0.45 
PD^H 
-0.47 
-0.39 
-0.55* 
PD
a
U 
BECLOMETHASONE 
PD^U 
DD 
ND 
flj 
0 . 7 Г 
-0.44 
-0.09 
-0.42 
-0.57' 
•O.ll 
-О.бГ 
ΡΟ,,Η PD^U 
BASELINE PERIOD 2 
PD
a
U 
D D 
ND 
ß2 
0.75-
-0.66' 
-0.54* 
-0.68" 
-0.75' 
-0.51' 
-0.77' 
PDJOH PDaU 
NEDOCROMIL SODIUM 
PD^U 
DD 
ND 
ß j 
0.94"* 
-0.77-
-0.16 
-0.60" 
PDjoH 
-0.70" 
-0.21 
-0.53-
PDaU 
*p<0.05; +*p< 0.005; 
• p<0.05 vsPDaH. 
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8.4 RESULTS 
Twenty-three patients completed the study as described in paragraph 7.4. The 
diary cards of 17 patients could be evaluated for asthma symptoms. 
Diary card. No differences were found between daytime dyspnoea, nighttime 
dyspnoea, coughing and ßi-agonist use recorded on the diary cards during both baseline 
periods. The treatment effects on ß2-agonist use have already been described in chapter 7. 
Coughing did not change during placebo or active treatment. Daytime and nighttime 
dyspnoea, and ß2-agonist use were significantly lower after eight weeks of treatment with 
bedomethasone than during the baseline period (p=0.01, p=0.002 and p=0.002, 
respectively) (figures 8.1 and 7.3). 
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Figure 8.1: Mean values (± SE) for daytime (panel A) and nighttime dyspnoea (panel В), registered ση a 
visual analog scale during the last week of baseline and bedomethasone (open bars) and nedocromil sodium 
treatment (shaded bars). 
NS: not significant. 
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Nedocromil sodium, however, could not improve these parameters after 8 weeks of 
treatment compared to the baseline. After 8 weeks of treatment daytime dyspnoea and ß2-
agonist use were significantly lower during beclomethasone than during nedocromil 
sodium. 
The correlations between the asthma symptom scores derived from the diary 
cards and PDJiistamine and PDjoUNDW are shown in table 8.1. Throughout the whole 
study PDJiistamine and PD^UNDW were significantly correlated. In all four periods ßj-
agonist use was also consistently correlated to the PDjnUNDW (table 8.1), but to the 
PDjohistamine. During beclomethasone treatment the PDaUNDW was significantly 
correlated to daytime dyspnoea and ß2-agonist use, whereas there was no correlation with 
the PDahistamine for these parameters. In baseline period 2, correlations were found 
between all parameters and the РО
л
 values. The correlation coefficient between 
PDJQUNDW and ßj-agonist use was significantly higher than that between PDjohistamine 
and ß2-agonist use (p=0.03). During nedocromil sodium treatment both PD^histamine and 
PDJOUNDW showed a significant correlation to daytime dyspnoea and ß2-agonist use. No 
correlations were found between coughing and РО
ш
 values. Significant correlations were 
found between coughing and nighttime dyspnoea in all periods (r.=0.69, r.=0.49, 
r.=0.65 and r,=0.63 respectively, p<0.05). Daytime dyspnoea and coughing showed 
only a significant correlation during both placebo periods (r,=0.64 and ^=0.65 
respectively, ρ < 0.05), but not during active treatment. 
Daytime dyspnoea and ß2-agonist use showed significant correlations in all four periods 
(^=0.87, r,=0.73, r.=0.84 and ^=0.49 respectively, p<0.05). 
Perception of dyspnoea during bronchial challenge. The dyspnoea scores during 
the bronchoprovocation tests could be evaluated in 19 patients. There was no difference in 
increase in dyspnoea and fall in FEV, during histamine and distilled water challenge 
(figure 8.2). However, during distilled water challenge the increase in coughing was 
significantly more pronounced than during histamine inhalation (p=0.002). There was no 
significant correlation between the PDj, values and the increase in dyspnoea and coughing 
during the tests. 
The correlations between the increase in dyspnoea and the fall in FEV, during histamine 
and UNDW challenge are shown in figure 8.3 for baseline and active treatment periods. 
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During distilled water inhalation there was a significant correlation between the increase 
in dyspnoea and fall in FEV, in all four periods, whereas during histamine challenge no 
correlations were present. 
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Figure 8.2: Mean increases (+_ SE) in dyspnoea and cough, registered on a visual analog scale, and mean 
falls in FEVt during histamine and distilled water challenge in allergic asthmatic subjects. NS: not 
significant. 
No correlation could be found between the increase in coughing and the fall in FEV, 
during either of the tests. 
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Figure 8.3: The relationship between the fall in FEV, and increase in dyspnoea caused by histamine and 
distillai water duillenge during baseline (A and D), beclomethasone (B and E) and nedocromil sodium 
treatment (C and F) 
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8.5 DISCUSSION 
Our data, presented in this chapter, demonstrated a significant decrease in 
daytime and nighttime dyspnoea and B2-agonist use during beclomethasone compared to 
baseline values, whereas nedocromil sodium had no effect on these parameters. 
Although there was a good correlation between the histamine- and UNDW-
induced bronchoconstnctor response throughout the whole study, distinct differences were 
found between the correlations of the two bronchoconstnctor responses and the asthma 
symptom scores as recorded on the diary cards. In baseline period 1, the PDMUNDW 
significantly correlated to ß2-agonist use and during beclomethasone treatment the 
PDJOUNDW significantly correlated to daytime dyspnoea and ß2-agonist use, whereas 
PDjohistamine did not correlate in these cases. In baseline period 2, the correlation 
between ß2-agonist use and PDJDUNDW was significantly stronger than that between ß2-
agonist and PDJiistamine. The fact that asthma symptom scores correlates slightly better 
with PDMUNDW than with PDJiistamine, supports the idea that bronchoprovocation with 
the physical stimulus UNDW, correlates better with asthma symptoms than 
pharmocological stimuli like histamine do 7•'3. 
During the study there was a consistent relationship between ß2-agonist use and 
daytime dyspnoea, indicating that the patients were using their bronchodilator medication 
on demand. Furthermore, this correlation indicates that additional ß2-agonist use reflects 
the severity of dyspnoea and indirectly the severity of asthma, as pointed out by others l*. 
Also ß2-agonist use and PD^UNDW showed a consistent correlation, which was not 
affected by treatment-induced changes of the parameters involved. 
During bronchial challenge with distilled water the increase in dyspnoea 
significantly correlated to the fall in FEV, in all treatment periods, whereas during 
histamine challenge no correlations were found between both parameters. Apparently the 
perception of dyspnoea during histamine challenge in this group of patients is not related 
to the decrease in airflow. As mentioned above, the pathophysiologic mechanisms 
underlying the histamine- and distilled water-induced bronchoconstrictor response are 
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clearly different. Involvement of mediator release or vagally mediated reflexes '^ 15 may 
well contribute to a better perception of changes in lung function during distilled water-
induced bronchoconstriction than during histamine. 
In this study the magnitude of the increase in dyspnoea and fall in FEV, were not 
significantly different in the two tests. The increase in coughing during distilled water 
inhalation was significantly more pronounced than during histamine inhalation. Both 
cough and bronchoconstrictor reflexes are closely related and can potentiate each other ". 
Cough receptors can be stimulated independently from bronchconstriction, but they may 
also be caused by a bronchoconstrictor response ". Inhalation of irritant aerosols induces 
coughing in both normal and asthmatic subjects, which implies that coughing is a normal 
phenomenon l7. Thus, coughing, although registered by the patients considerably more 
during distilled water inhalation, seems not to be related to a better perception of 
dyspnoea. 
We conclude that asthma symptom scores recorded on diary cards correlate 
slightly better with UNDW- than with histamine-induced bronchoconstriction. A 
consistent correlation was found between bronchial hyperesponsiveness to distilled water 
and ß2-agonist use. During bronchial challenge with distilled water the change in dyspnoea 
significantly correlated with the fall in FEV,, but not during histamine challenge. These 
results suggest a closer relationship between asthma symptoms and bronchial 
hyperresponsiveness to UNDW than between asthma symptoms and bronchial 
hyperresponsiveness to histamine. 
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In Chapter 1 a general introduction to this thesis is given and an outline of the 
aims of the different studies. 
Asthma is a disease characterized by paroxysms of dyspnoea, wheezing and cough 
caused by an increased bronchial hyperresponsiveness. This hyperresponsiveness is 
defined as an exaggerated bronchoconstrictor response of the airways on exposure to a 
small quantity of non-specific stimuli which do not provoke such a reaction in normal 
subjects. Bronchial hyperresponsiveness is related to inflammation in the airways, diurnal 
variation in lung function and reversibility of bronchoconstriction to ßj-agonsts. Asthma 
severity and the clinical prognosis of asthma with regard to the development of chronic 
obstructive pulmonary disease and further decline in lung function are related to the seve-
rity of bronchial hyperresponsiveness. The assessment and pharmacological modulation of 
bronchial hyperresponsiveness in asthmatic subjects is the main subject in this thesis. 
Bronchial hyperresponsiveness is usually assessed by provocation with histamine or 
methacholine inhalation challenges. Histamine and methacholine mainly act directly on 
airway smooth muscles, in contrast to physical stimuli which act indirectly. In susceptible 
subjects provocation with physical stimuli causes mediator release in the airway wall, 
finally resulting in airway smooth muscle contraction. Thus, physical stimuli may assess a 
more complete pathway of bronchial hyperresponsiveness than pharmacological stimuli. It 
has been suggested that these physical stimuli cause better correlations between bronchial 
hyperresponsiveness to UNDW and asthma symptoms than between bronchial hyper-
responsiveness to histamine or methacholine and asthma symptoms. 
The main puipose of this thesis is to investigate whether a physical stimulus like distilled 
water has advantages over histamine in the assessment of bronchial hyperresponsiveness 
in asthmatic subjects. 
In Chapter 2 we investigated the reproducibility of the histamine provocation test 
by means of the Astma Provocation System (APS), a breath-actuated dosimeter, in nine 
asthmatic patients. The histamine provocation test with the dosimeter, performed on two 
different days, showed a good reproducibility with a standard deviation for repeated 
measurements of 10.4%. 
The APS dosimeter technique was further compared to the 2-minute tidal breathing tech-
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nique with the Wright nebulizer in fifteen patients with dyspnoea and suspected bronchial 
hyperresponsiveness. The tidal breathing technique is a simple, and inexpensive method. 
However, various factors like flow rate of the nebulizer, breathing frequency, inspiration 
volume and breath-holding time must be standardized to get reproducible results. The 
dosimeter technique is a more sophisticated and more expensive method with the 
advantage that the exact provocative dose of inhaled agent is known. 
Both techniques showed a good correlation (r=0.93, ρ <0.0005) and equally separated 
hyperresponsive from non-hyperresponsive subjects. The limit of agreement (-102% and 
+ 83%) and 95% confidence limit (+27%) between the two techniques show that both 
techniques are not fully exchangeable. 
In Chapter 3 we reviewed the literature on distilled water-induced bronchocon-
striction. 
The mechanism underlying the distilled water-induced bronchoconstrictor response 
is probably multifactorial. The non-isotonicity of the aerosol appears to be the trigger for 
bronchoconstnction in asthmatics, whereas normal subjects do not show this reaction to 
hypotonic or hypertonic aerosols. The acidity and titrability of the acid enhance the distil­
led water-induced bronchoconstrictor response. The protective effect of atropine and a 
high dose of ipratropium bromide on the UNDW-induced bronchoconstrictor response 
suggests at least a partial involvement of the autonomic nervous system. Also the release 
of mediators from inflammatory cells, especially the mast cell, are involved. Cromoglyca-
te and nedocromil sodium can totally inhibit the UNDW-induced bronchoconstriction. 
Furthermore, leukotrienes D, and E4 may also play a role, since specific antagonists can 
diminish the UNDW-induced bronchoconstriction. 
The UNDW-induced bronchoconstrictor response showes a significant correlation 
to histamine- and methacholine-induced bronchoconstriction in adults, but not in children. 
The effects of exercise and cold air hyperventilation are significantly correlated to 
UNDW-induced responses. Exercise-induced bronchoconstriction showed the closest 
relationship to the UNDW-induced bronchoconstrictor response, and a common pathophy­
siologic mechanism has been suggested. 
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In Chapter 4 we described the protocol of the distilled water provocation test used 
in the present studies in detail and investigated their reproducibility, relation to histamine 
challenge and duration of bronchoconstrictor response after UNDW inhalation. 
The reproducibility of the UNDW-induced bronchoconstrictor response was 
investigated with an short-term interval of 2 to 3 weeks and a long-term interval of 
approximately 3 months in two groups of 17 and 16 asthmatic patients respectively. To 
quantify the UNDW bronchoconstrictor response, several parameters derived from a 
semi-logarithmic dose-response curve were compared, i.e. the PDjnUNDW, the area 
under the curve (AUG), the reactivity and the sensitivity. The results showed a good 
short-term and long-term reproducibility of the UNDW-induced bronchoconstrictor 
response as measured with the PDjoUNDW, the sensitivity and AUG, whereas the 
reactivity was not reproducible. The PD^UNDW and the sensitivity showed the least 
variation as measured with the Standard deviation for repeated measurements. 
The duration of the UNDW-induced bronchoconstriction was investigated in 12 
asthmatic patients. All patients showed a fall in FEV, of more than 20 % after UNDW 
inhalation. Although there was a wide range in spontaneous recovery after the maximal 
bronchoconstriction was obtained, the bronchoconstrictor effect decreased in all subjects 
within 5 minutes after inhalation of the distilled water. 
In 16 atopic asthmatic subjects the distilled water-induced bronchoconstrictor 
response was compared to histamine induced-bronchoconstriction. The PDBUNDW and 
PDJiistamine were significantly correlated (r=0.72, p=0.002). 
In Chapter 5 we investigated whether histamine inhalation could cause refrac-
toriness to bronchoconstriction induced by UNDW or a second histamine challenge in 
nine asthmatic patients. Refractoriness or tachyphylaxis in bronchial challenge is a 
phenomenon of a substantially attenuated bronchoconstrictor réponse after re-exposure to 
the same stimulus within several hours after the first challenge. Pre-exposure to other 
stimuli can also cause refractoriness. In our study, preinhalation of histamine induced a 
significant diminished bronchoconstrictor response to UNDW. The mean PD^UNDW 
increased from 3.5 ± 0.8 ml to 11.8 ± 2.6 ml after histamine challenge (p < 0.01). 
Repeated inhalation of histamine did not change the bronchoconstrictor response to his-
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lamine within one hour after rechallenge. The magnitude of refractoriness to UNDW 
inhalation after preinhalation of histamine was correlated to the hyperresponsiveness to 
histamine (r = 0.73, ρ < 0.05). This indicates that histamine-induced refractoriness to 
UNDW seems to be related to the degree of bronchial hyperresponsiveness. 
In chapter 6 we investigated the protective properties of terbutaline and a high 
dose of ipratropium bromide on the UNDW-induced bronchoconstrictor response. 
UNDW-induced bronchoconstriction can be inhibited by ß2-agonists, like fenoterol and 
salbutamol, drugs with mast cell stabilizing properties like cromoglycate, and anti-
cholinergic drugs like atropine. Ipratropium bromide, however, in a clinical effective dose 
of 40 to 80 Mg has been reported to have no effect on UNDW-induced bronchocon-
striction. The protective properties of ipratropium bromide in UNDW challenge, 
therefore, are not clear. In a randomized, double-blind, placebo-controlled study, we 
investigated the protective effects of ipratropium bromide 160 Mg and 320 Mg and 
terbutaline 500 Mg on UNDW-induced bronchoconstriction in nine stable asthmatic 
patients. To compare the drug effects we determined the PD^UNDW and the reactivity 
and the sensitivity of the UNDW dose-response curve. Both drugs showed a significant 
increase (p< 0.001) in baseline FEV, with no significant difference between the drugs or 
the doses of ipratropium bromide. Preinhalation of ipratropium bromide 320 Mg and 
terbutaline 500 Mg inhibited UNDW-induced bronchoconstriction as measured by PD ,^-
UNDW and sensitivity (p<0.01), whereas ipratropium bromide 160 Mg had no protective 
effect. There was no correlation between the increase in baseline FEV, and the increase in 
PDJOUNDW, indicating that the protective effect on UNDW-induced bronchoconstriction 
is not dependent on the bronchodilation induced by terbutaline and ipratropium bromide. 
It is also concluded that the UNDW-induced bronchoconstriction is at least partly vagally 
mediated. 
In Chapter 7 the pharmacological modulation of bronchial hyperresponsiveness in 
atopic asthmatic subjects is investigated. In a randomized crossover, double-blind study 
we compared the effects of inhaled nedocromil sodium, 4 mg q.i.d., with inhaled be-
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clomethasone dipropionate, 200 /ig q.i.d. in 23 atopic asthmatic patients. After a 3-week 
single-blind wash-out placebo period and after 4 and 8 weeks of active treatment, drug 
effects were assessed with histamine and UNDW inhalation challenges, baseline lung 
function and ß2-agonist use registered on a diary card. Treatment with beclomethasone 
caused a significant increase in baseline lung function 
(p<0.005) and daily peakflow measurements (p<0.05) and a decrease in bronchial 
hyperresponsiveness to histamine (p<0.0005) and UNDW (p<0.0005) as compared to 
the baseline. Nedocromil sodium decreased the histamine responsiveness (p< 0.005), but 
not the UNDW responsiveness, and it did not improve baseline lung function and peak 
flow measurements, ßj-agonist use was significantly diminished after an 8-week treatment 
with beclomethasone, whereas nedocromil sodium had no such an effect. The improve-
ment in bronchial hyperresponsiveness to histamine and UNDW, the peakflow measu-
rements and the changes in ß2-agonist use were more pronounced for beclomethasone than 
for nedocromil sodium (p<0.05). 
After 8 weeks of treatment with beclomethasone bronchial hyperresponsiveness to 
histamine had improved significantly more than after 4 weeks of treatment, whereas the 
PDJOUNDW was not significantly different after 4 and 8 weeks of treatment. The change 
in PD^histamine correlated to the change in PD^UNDW after 8 weeks of treatment but 
not after 4 weeks of treatment. These differences in time course of drug-induced changes 
indicate that histamine and distilled water challenge assess bronchial hyperresponsiveness 
on a different level, and they may confirm differences in the underlying mechanisms. 
Chapter 8 describes the correlations between asthma symptom scores and ßj-
agonist use, both registered on a diary card, and bronchial hyperresponsiveness to his-
tamine and distilled water, during the study described in chapter 7. Furthermore, asthma 
symptoms were recorded during bronchial challenge and correlated to changes in lung 
function during testing. 
After 8 weeks of treatment with beclomethasone, asthma symptom scores 
registered on a diary card demonstrated a more significant decrease in daytime dyspnoea 
(p=0.002) and ß2-agonist use (p=0.002) than after treatment with nedocromil sodium. 
The distilled water-induced bronchoconstrictor response correlated slightly better and 
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more consistently to daytime dyspnoea and ßj-agonist use than histamine-induced 
bronchoconstriction. 
Assessment of the change in dyspnoea during bronchial challenge demonstrated a 
significant correlation between the increase in dyspnoea and the fall in FEV, during 
distilled water inhalation but not during inhalation of histamine. 
These results indicate that differences in pathophysiologic mechanisms underlying 
bronchial hyperresponsiveness to histamine and distilled water are reflected in their 
relationship to ß2-agonist use and daytime dyspnoea registered on diary cards and during 
bronchial challenge. 
143 
Chapter 9 
CONCLUSIONS 
1. The standardized UNDW provocation test is a reliable, sensitive and reproducible 
method of assessing bronchial hyperresponsivleness in asthmatic subjects. The 
PDJOUNDW and sensitivity of the dose-response curve are the most sensitive 
thresholds reflecting the distilled water-induced bronchoconstrictor response. 
2. The APS dosimeter technique in histamine challenge is a well reproducible method 
for the assessment of bronchial hyperresponsiveness. The dosimeter method is 
comparable to the 2-minute breathing technique with the Wright nebulizer, al-
though the threshold values are not fully exchangeable. 
3. Preinhalation of histamine induces refractoriness to UNDW-induced bronchocon-
striction but not for the histamine-induced bronchoconstrictor response. The 
magnitude of refractoriness is related to the severity of bronchial hyperresponsive-
ness to histamine. 
4. At a similar degree of bronchodilatation induced by high and low dose ipratropium 
bromide, high dose ipratropium bromide inhibits UNDW-induced bronchoconstric-
tion. Hence, the response to inhaled UNDW is at least partly vagally mediated. 
5. Eight weeks of treatment with beclomethasone, 800 Mg daily, improves baseline 
lung function, morning and evening peakflow measurements, bronchial hyperres-
ponsiveness to histamine and distilled water, and decreases daytime dyspnoea and 
ß2-agonist use compared to baseline measurements and 8 weeks of treatment with 
nedocromil sodium, 16 mg daily, in atopic asthmatic subjects. Nedocromil sodium 
only improved bronchial hyperresponsiveness to histamine after 4 and 8 weeks of 
treatment. 
6. Bronchial hyperresponsiveness to UNDW shows a closer and more consistent 
correlation to daytime dyspnoea and ß2-agonist use registered on a diary card than 
histamine-induced bronchoconstriction. Furthermore, during distilled water 
challenge a significant correlation between increase in dyspnoea and fall in FEV, 
has been demonstrated, which is not the case during histamine challenge. 
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7. UNDW compared to histamine challenge is equally sensitive in detecting changes 
in bronchial hyperresponsiveness induced by anti-inflammatory drugs as beclome-
thasone. 
8. During UNDW-induced bronchoconstriction increases in dyspnoea are correleted 
to decreases in FEV,, but not during histamine challenge. 
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In Hoofdstuk 1 wordt de algemene inleiding gegeven van dit proefschrift met de 
hieraan ten grondslag liggende vraagstellingen. 
Astma is een ziektebeeld dat gekarakteriseerd wordt door aanvallen van 
kortademigheid, piepen en hoesten als uiting van een toegenomen bronchiale 
hyperreaktiviteit. Deze bronchiale hyperreaktiviteit wordt gedefinieerd als een overmatige 
bronchusvemauwing van de luchtwegen, als reactie op blootstelling van die luchtwegen 
aan een kleine hoeveelheid aspecifieke prikkel, die in die hoeveelheid geen reactie 
veroorzaakt bij niet-astmatische proefpersonen. Bij patiënten met astma wordt een 
toename van ontstekingscellen in het longweefsel gezien. De mate van bronchiale 
hyperreaktiviteit is geassocieerd met de emst van het ontstekingsproces in de luchtwegen, 
de variatie in longfunctie over de dag gemeten, met name het verschil in luchtweg-
obstructie s'morgens en s'avonds, en de mate van reversibiliteit van de luchtweg-
vernauwing na inhalatie met een ß2-mimeticum, een luchtwegverwijdend medicament. De 
emst van het astma, de klinische prognose van het astma met betrekking tot het 
ontwikkelen van chronisch obstructief longlijden en de mate van afname van de 
longfunctie zijn gerelateerd een de mate van bronchiale hyperreaktiviteit. Om deze 
bovengenoemde redenen staan het meten en de farmacologische beïnvloeding van 
bronchiale hyperreaktiviteit centraal in dit proefschrift. 
Bronchiale hyperreaktiviteit wordt veelal gemeten met bronchoprovocatie testen 
met histamine of methacholine. Histamine en methacholine zijn farmacologische prikkels 
die met name een direct constrictief effect hebben op de gladde spieren van de 
luchtwegen, in tegenstelling tot fysische prikkels die op meer indirecte wijze een 
bronchoconstrictie veroorzaken. Blootstelling aan fysische prikkels, veroorzaakt in 
hiervoor gevoelige patiënten het vrijkomen van mediatoren in de luchtwegwand, die op 
hun beurt een constrictie van de gladde spiercellen in de luchtwegen kunnen veroorzaken 
met een luchtwegvemauwing tot gevolg. Fysische prikkels meten dus een meer compleet 
traject van bronchiale hyperreaktiviteit dan farmacologische prikkels. Mede hierom wordt 
in de literatuur een betere correlatie tussen bronchoprovocatie tests met fysische prikkels 
en astmasymptomen gesuggereerd dan tussen farmacologische prikkels en astma-
symptomen. 
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Verneveld gedistilleerd water is zo'n fysische prikkel, vergelijkbaar met inspanning. 
Gedistilleerd water is een specifieke prikkel voor het meten van bronchiale 
hyperreaktiviteit bij astmapatiënten daar bij normale proefpersonen, in tegenstelling tot de 
farmacologische prikkels, geen bronchoconstrictie kan worden bewerkstelligd. 
De centrale vraagstelling in dit proefschrift is dan ook of fysische stimuli zoals 
gedistilleerd water voordelen hebben boven histamine in het meten van bronchiale 
hyperreaktiviteit bij astmapatiënten. 
In Hoofdstuk 2 onderzochten we bij negen astmapatiënten de reproduceerbaarheid 
van de histamine provocatietest uitgevoerd met het Astma provocatie systeem (APS), een 
inademings geactiveerde dosimeter. De histamine provocatietest met deze dosimeter werd 
uitgevoerd op twee verschillende dagen en liet een goede reproduceerbaarheid zien met 
een standaard deviatie voor herhaalde metingen van 10.4%. 
De techniek met de APS dosimeter werd verder vergeleken met de methode volgens 
Hargreave, waarbij de patiënt via een Wright vemevelaar gedurende 2 minuten histamine 
inademt met rustademhaling. De twee methoden werden vergeleken bij een groep van 
vijftien patiënten met klachten van kortademigheid en verdenking op bronchiale 
hyperreaktiviteit. De methode met de Wright vemevelaar is een eenvoudige en goedkope 
methode, echter diverse factoren zoals de stroomsnelheid van de lucht door de jet-
vernevelaar, de ademfrequentie en het adempatroon van de patiënt dienen 
gestandaardiseerd te worden voor het verkrijgen van reproduceerbare resultaten. De 
dosimeter techniek is een meer ingewikkelde en duurdere methode, met als voordeel dat 
de exacte dosis van de door de patiënt ingeademde histamine bekend is. Beide technieken 
toonden een goede correlatie (r=0.93, ρ < 0.0005) en maakten in de zelfde mate 
onderscheid tussen responders en niet-responders. De limiet van overeenstemming, welke 
aangeeft uitgaande van een meting met de Wright vemevelaar in welke mate de APS 
methode hiervan kan afwijken (-102% and +83%) en het 95% betrouwbaarheid interval 
(+. 27%) geven echter aan dat de resultaten van de twee technieken niet geheel 
uitwisselbaar zijn. 
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In Hoofdstuk 3 wordt een overzicht gegeven van de literatuur met betrekking tot 
de bronchoconstnctie geïnduceerd door inhalatie van ultrasoon verneveld gedistilleerd 
water. 
Het onderliggende mechanisme van deze bronchoconstrictie wordt waarschijnlijk 
door diverse factoren bepaald. Het niet isotone karakter van het gedistilleerde water lijkt 
de uitlokkende factor te zijn welke aanleiding is tot bronchoconstrictie bij astmatische 
patiënten. Inhalatie van hypotone of hypertone aerosolen veroorzaakt geen reactie bij 
niet-astmatische proefpersonen. De zuurgraad en de mate waarin dat zuur titreerbaar is 
kunnen de gedistilleerd water geïnduceerde bronchoconstrictie versterken. Atropine en 
hoge doses ipratropium bromide, beiden anticholinergica, hebben een beschermend effect 
bij inhalatie van gedistilleerd water. Dit beschermend effect van atropine en ipratropium 
bromide suggereert dat het autonome zenuwstelsel tenminste gedeeltelijk betrokken is bij 
de bronchoconstrictie welke door inhalatie van gedistilleerd water wordt veroorzaakt. 
Mediatoren die vrij komen uit ontstekingscellen in de luchtwegen, zoals de mestcel, zijn 
ook bij deze reactie betrokken. Cromoglicinezuur en nedocromil, medicijnen die onder 
andere een stabilisatie van de mestcel kunnen geven en hiermee het vrijkomen van 
mediatoren voorkomen, kunnen een volledige bescherming geven voor gedistilleerd water 
geïnduceerde bronchoconstrictie. Ook de leukotrieën D4 en E4 spelen een rol in het 
onderliggend mechanisme, daar specifieke antagonisten de luchtweg vernauwende respons 
op inhalatie van gedistilleerd water kunnen doen afnemen. 
De door inhalatie van vemeveld gedistilleerd water veroorzaakte 
bronchoconstrictieve respons correleert met de respons veroorzaakt door inhalatie van 
histamine en methacholine bij volwassen patiënten. Bij kinderen is geen correlatie tussen 
beide responsen gevonden. Ook inspanning geïnduceerde bronchoconstrictie en 
bronchoconstrictie veroorzaakt door hyperventilatie met koude lucht is significant 
gecorreleerd aan de respons na inhalatie van gedistilleerd water, waarbij inspanning en 
gedistilleerd water de sterkste overeenkomst laten zien. Om deze reden wordt een 
gemeenschappelijk pathophysiologisch mechanisme bij inspanningsastma en de 
bronchoconstrictie door inhalatie van gedistilleerd water verondersteld. 
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Hoofdstuk 4 beschrijft het protocol van de bronchoprovocatie test met verneveld 
gedistilleerd water zoals het is toegepast in de in dit proefschrift beschreven studies. De 
reproduceerbaarheid van de dosis-respons curve werd onderzocht met een kortdurend 
interval van 2 à 3 weken bij 17 astmapatiënten en met een langdurig interval van 
ongeveer 3 maanden bij 16 astmapatiënten. Voor het vergelijken van de door inhalatie 
van gedistilleerd water geïnduceerde responsen werden diverse parameters, welke de 
semi-logaritmische dosis-respons curve beschrijven, zoals de drempelwaarde PD^UNDW, 
het oppervlak onder de dosis-respons curve, de sensitiviteit en de reactiviteit, berekend. 
De PDaUNDW, het oppervlak onder de dosis-response curve en de sensitiviteit, een 
lineare regressie van de dosis-response curve toonden een goede kortdurende en lang-
durende reproduceerbaarheid, waarbij de PDSUNDW en sensitiviteit de kleinste standaard 
deviatie voor herhaalde metingen lieten zien. De reactiviteit, de hoek van het meest steile 
deel van de curve, was niet reproduceerbaar. 
De tijdsduur van de bronchoconstrictie na het bereiken van de drempelwaarde 
PDJOUNDW werd onderzocht bij 12 astmapatiënten. Alhoewel er een grote variatie in 
spontaan herstel van de bronchoconstrictie bestond werd er een plateau van het 
bronchoconstrictieve effect bereikt tussen 30 seconden en 3 minuten na inhalatie, terwijl 
bij alle patiënten het spontane herstel binnen 5 minuten na inhalatie aanving. 
Bij 16 atopische astmapatiënten werd de histamine respons vergeleken met die 
van verneveld gedistilleerd water. De PD^UNDW en PDJiistamine toonde een 
significante correlatie (r=0.72, p=0.002). 
In Hoofdstuk 5 onderzochten we bij 9 astmapatiënten of inhalatie van histamine 
een refractaire periode kon veroorzaken voor een provocatietest met gedistilleerd water of 
een tweede histamine provocatietest. Tachyphylaxie of refractaire periode bij 
bronchoprovocatie tests is een fenomeen waarbij de mate van bronchoconstrictie na 
blootstelling aan een bepaalde stimulus afneemt, indien binnen enkele uren na de eerste 
test de patiënt opnieuw wordt bloot gesteld aan dezelfde stimulus. Dit fenomeen kan ook 
optreden bij verschillende stimuli. In ons onderzoek werd na een histamine provocatie-
test, nadat de FEV, spontaan hersteld was tot de basale uitgangswaarde, een tweede 
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provocatietest verricht met histamine of gedistilleerd water. Dit spontaan herstel trad 
binnen een uur op. Inhalatie van histamine veroorzaakte een tachyphylaxie voor inhalatie 
van gedistilleerd water. De gemiddelde PD^UNDW nam toe van 3.5 +. 0.8 ml tot 11.8 
+. 2.6 ml na inhalatie van histamine (p<0.01). Histamine inhalatie veroorzaakte geen 
tachyphylaxie voor een tweede provocatietest met histamine. De verandering in 
PDJJUNDW tengevolge van de tachyphylaxie was gecorreleerd aan de hoogte van de 
histamine drempel (r=0.73, ρ < 0.05), wat aangeeft dat de mate van de door histamine 
veroorzaakt tachyphylaxie voor inhalatie van gedistilleerd water omgekeerd geassocieerd 
is met de emst van bronchiale hyperreaktiviteit. 
Hoofdstuk 6 beschrijft een studie naar de beschermende effecten van ipratropium 
bromide en terbutaline voor de bronchoconstrictie veroorzaakt door inhalatie van 
gedistilleerd water bij astmapatiënten. ß2-mimetica, zoals salbutamol en fenoterol, 
medicijnen met mestcel stabiliserende eigenschappen zoals cromoglicinezuur en 
anticholinergica zoals atropine kunnen de bronchoconstrictie veroorzaakt door inhalatie 
van gedistilleerd water remmen of voorkomen. Ipratropium bromide, een 
anticholinergicum, heeft echter in de klinisch effectieve dosis van 40 of 80 Mg geen effect 
op de door gedistilleerd water geïnduceerde luchtwegvemauwing. De beschermende 
effecten van ipratropium bromide zijn daarom niet duidelijk. In een gerandomiseerde, 
dubbel blinde, placebo gecontroleerde studie onderzochten we om deze reden, de 
beschermende effecten van ipratropium bromide 160 en 320 ßg en terbutaline 500 /ig 
voor gedistilleerd water geïnduceerde bronchusobstructie. Om de effecten van de 
medicatie te beoordelen, vergeleken we diverse parameters die de dosis-respons curve 
beschrijven, zoals de PDMUNDW, de sensitiviteit en de reactiviteit. Beide medicijnen 
veroorzaakten een significante toename van de basale FEV, (p<0.01), waarbij er geen 
onderlinge verschillen waren tussen beide medicamenten en beide doses. Ipratropium 320 
Mg en terbutaline 500 Mg gaven een remming van de door gedistilleerd water 
geïnduceerde bronchusobstructie, gemeten met de PDaUNDW en sensitiviteit (p<0.01), 
terwijl de lage dosis ipratropium bromide geen protectie gaf. Er bestond geen correlatie 
tussen de mate van toename in FEV, en de mate van protectie, zodat het beschermende 
effect van de geteste medicijnen niet veroorzaakt wordt door hun luchtweg verwijdend 
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effect. Tevens kunnen wij concluderen dat het autonome zenuwstelsel tenminste ten dele 
betrokken is bij de luchtwegvemauwing tengevolge van inhalatie van gedistilleerd water. 
In Hoofdstuk 7 onderzochten we of de bronchiale hyperreaktiviteit van atopische 
astmapatiënten door medicatie beïnvloed kan worden. We vergeleken in een dubbel 
blinde, gerandomiseerde cross-over studie de effecten van nedocromil sodium, 4 maal 
daags 4 mg per inhalatie, met beclomethason dipropionaat, 4 maal daags 200 Mg per 
inhalatie, bij 23 atopische astmapatiënten. Na een enkel-blinde placebo uitwas periode 
van drie weken, en na 4 en 8 weken behandeling met een dubbel-blind werkzaam 
medicament werden de effecten geëvalueerd met histamine en gedistilleerd water 
provocatietests, basale longfunctie, piekstroom metingen en ß2-agonist gebruik, 
bijgehouden met een dagboekje. Tijdens de behandelingsperiode met beclomethason werd 
een significante verbetering van de longfunctie (p< 0.005) en de piekstroom meting 
gezien (p<0.05) en een afname van de bronchiale hyperreaktiviteit voor histamine 
(p< 0.0005) en gedistilleerd water (p< 0.0005). Nedocromil sodium verminderde de 
bronchiale overgevoeligheid voor histamine (p< 0.005), maar niet voor gedistilleerd 
water, en er werden geen veranderingen in longfunctie en piekstroom metingen gevonden. 
Het ß2-agonist gebruik verminderde significant na 8 weken behandeling met 
beclomethason maar niet na behandeling met nedocromil sodium. De effecten van de 
behandeling met beclomethason, gemeten met histamine en gedistilleerd water provocatie-
tests, basale longfunctie waarden, piekstroom metingen en ß2-mimeticum gebruik, waren 
superieur aan de effecten tijdens nedocromil sodium behandeling (p<0.05). 
Na 8 weken behandeling met beclomethason verbeterde de histamine drempel nog 
significant ten opzichte van 4 weken behandeling, terwijl de PDMUNDW niet verschillend 
was na 4 en 8 weken behandeling. De veranderingen in PDJiistamine en PDallNDW 
correleerden niet met elkaar na 4 weken behandeling, echter wel na 8 weken behandeling 
(r. = 0.64, ρ<0.05). Dit verschil in tijdsduur waarin de veranderingen in bronchiale 
hyperreaktiviteit bereikt worden suggereert dat de stimuli histamine en gedistilleerd water 
bronchiale hyperreaktiviteit op een verschillend niveau meten. Deze veronderstelling 
wordt tevens ondersteund door wat bekend is over het onderliggende mechanisme. 
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Hoofdstuk 8 beschrijft de correlaties tussen astmaklachtenscores, ß2-mimeticum 
gebruik, en de bronchiale overgevoeligheid voor histamine en gedistilleerd water, tijdens 
de studie beschreven in hoofdstuk 7. De klachtenscores en het ß2-mimeticum gebruik 
werden door de patiënten in een dagboekje bijgehouden. Tevens werden astma-
symptomen geregistreerd tijdens de histamine en gedistilleerd water bronchoprovocvatie-
tests en gecorreleerd aan de veranderingen in longfunctie tijdens de tests. 
De dyspnoeklachten overdag en het ß2-mimeticum gebruik lieten na 8 weken 
behandeling met beclomethason een significant sterkere afname zien dan tijdens 
behandeling met nedocromil sodium (p=0.002 voor beiden). De PDaUNDW correleerde 
in geringe mate beter, maar met name meer consistent met de klachten van 
kortademigheid overdag en het ß2-mimeticum gebruik dan de histamine drempel met deze 
parameters correleerde. 
De toename van dyspnoeklachten tijdens de bronchoprovocatietests liet een 
significante correlatie zien met de daling in FEV, tijdens inhalatie met gedistilleerd water 
maar niet tijdens inhalatie met histamine. Deze bevindingen geven aan dat verschillen in 
de pathophysiologische mechanismen van bronchiale hyperreaktiviteit voor histamine en 
gedistilleerd water, weerspiegelt worden in hun relatie met klachtenscores, zoals 
kortademigheidklachten overdag en ß2-mimeticum gebruik geregistreerd in een dagboekje 
en tijdens bronchoprovocatietests. 
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CONCLUSIES: 
1. De gestandaardiseerde provocatietest met inhalatie van verneveld gedistilleerd 
water is een betrouwbare, sensitieve en reproduceerbare methode voor het meten 
van bronchiale hyperreaktiviteit in astmapatiënten. De PDjoUNDW en de 
sensitiviteit van de dosis-respons curve zijn de meest sensitieve drempelwaarden 
die de bronchoconstrictieve respons van gedistilleerd water weergeven. 
2. De APS dosimeter techniek bij bronchoprovocatietests met histamine is een goed 
reproduceerbare methode voor het meten van bronchiale hyperreaktiviteit. De 
techniek met de dosimeter is goed vergelijkbaar met de inhalatietechniek met de 
Wright vemevelaar gedurende 2 minuten rustademhaling. De drempelwaarden 
tussen deze twee technieken zijn echter niet geheel uitwisselbaar. 
3. Inhalatie van histamine voorafgaand aan een provocatietest met gedistilleerd 
water veroorzaakt een refractaire periode voor mist. Herhaalde provocatietests 
met inhalatie van histamine veroorzaakt geen tachyphylaxie voor histamine. De 
mate van de refractaire reactie van mist na histamine is gecorreleerd aan de 
histaminedrempel, en omgekeerd geassocieerd met de mate van bronchiale 
hyperreaktiviteit. 
4. Inhalatie van hoge en lage dosis ipratropium bromide veroorzaken bij astma-
patiënten een bronchodilatatie van dezelfde grootorde. Alleen de hoge dosis 
ipratropium bromide is in staat de bronchoconstrictie veroorzaakt door inhalatie 
van gedistilleerd water te verminderen. Hieruit volgt dat het autonome 
zenuwstelsel tenminste ten dele een rol speelt in de bronchoconstrictieve respons 
van de luchtwegen op inhalatie van gedistilleerd water bij astmapatiënten. 
5. Inhalatie van beclomethason, 800 ug per dag, gedurende acht weken verbetert de 
longfunctie, de piekstroom metingen s'morgens en s'avonds, de bronchiale 
hyperreaktiviteit voor histamine en verneveld gedistilleerd water en vermindert de 
dyspnoeklachten overdag en het Bï-mimeticum gebruik, in vergelijking met drie 
weken placebo medicatie en nedocromil sodium, 16 mg per dag, gedurende acht 
weken. 
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6. Bronchoprovocatie met gedistilleerd water, vergeleken met die met histamine, is 
gelijkwaardig sensitief in het meten van verandenngen in bronchiale 
hyperreactiviteit tengevolge van anti-inflammatoire medicijnen, zoals 
beclomethason. 
7. Bronchiale hyperreaktiviteit voor verneveld gedistilleerd water heeft een betere en 
meer consistente associatie met dyspnoeklachten overdag en ßj-mimeticum 
behoefte, geregistreerd in een dagboekje dan de histaminedrempel met deze 
parameters heeft. 
8. Tijdens bronchoprovocatie met verneveld gedistilleerd water bestaat er een 
correlatie tussen de toename van dyspnoeklachten en de afname van FEV,, welke 
tijdens bronchoprovocatie met histamine niet aanwezig is. 
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LIST OF ABBREVIATIONS 
AUG 
FEV, 
MEF» 
MEFJS 
PCahistamine 
PDahistamine 
PDJOUNDW 
POMUNDW 
UNDW 
SD 
SE 
Area under the dose-response curve 
Forced expiratory volume in 1 second 
Maximal expiratory flow at 50% of the vital capacity 
Maximal expiratory flow at 25% of the vital capacity 
Provocative concentration of histamine causing a 20% 
fall in FEV, 
Provocative dose of histamine causing a 20% fall in 
FEV1 
Provocative cumulative dose of UNDW causing a 20% 
fall in FEV1 
Provocative nebulizer output causing a 20% fall in 
FEV1 during UNDW challenge 
Ultrasonically nebulized distilled water 
Standard deviation 
Standard error 
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STELLINGEN 
Behorende bij het proefschrift 
Bronchial Hyperresponsiveness to 
Ultrasonically Nebulized Distilled Water 
and Histamine in Asthmatic subjects 
C.A.R. Groot 
Nijmegen, 29 september 1992 

1. Inhalatie van histamine voorafgaand aan de inhalatie van ultrasoon verneveld 
gedistilleerd water kan bij astmapatiënten een refractaire periode veroorzaken 
voor de door gedistilleerd water geïnduceerde bronchoconstrictie, waarbij de 
mate van deze tachyphylaxie omgekeerd evenredig is met de mate van bronchiale 
hyperreactiviteit (dit proefschrift). 
2. Het beschermende effect van ipratropium bromide voor bronchusobstructie, 
geïnduceerd door de inhalatie van ultrasoon verneveld gedistilleerd water, is 
dosis afhankelijk en is niet gecorreleerd aan de mate van luchtwegverwijding 
veroorzaakt door dit medicament (dit proefschrift). 
3. De behandeling van matig ernstige astmapatiënten met beclomethason in een 
dagdosis van 800 /xg gedurende 8 weken, is superieur aan de behandeling met 
nedocromil 16 mg daags (dit proefschrift). 
4. Astmasymptoomscores correleren beter met bronchiale hyperreactiviteit voor 
ultrasoon verneveld gedistilleerd water dan met bronchiale hypperreactiviteit voor 
histamine (dit proefschrift). 
5. Astmapatiënten hebben tijdens provocatietests met ultrasoon verneveld 
gedistilleerd water een betere perceptie van bronchusobstructie dan tijdens 
provocatie met histamine (dit proefschrift). 
6. Het ovarieel hyperstimulatie syndroom lijkt bij daartoe gevoelige patiënten astma 
te kunnen uitlokken. Bij het ziektebeeld worden gelijksoortige mediatoren 
vrijgemaakt. С Groot et al. Lancet 1991;337:112 
7. Bij patiënten die deelnemen aan longrevalidatie spelen psychosociale problemen 
vaak een centrale rol bij het instand houden van hun ziek zijn (eigen 
waarneming). 
8. De arts die een kind met een "eenvoudige" Wilms'tumor niet naar een 
kinderoncologisch centrum verwijst, dient zich te realiseren dat de kans op 
genezing van een recidief uitermate klein is. Ook voor deze patiënt geldt: "There 
is no second chance". J.J. Groot-Loonen et al. Arch Dis Childh 1990;65:968-
970. 
9. De arts onderschat vaak zijn voorbeeldfunctie met betrekking tot eet-, drink- en 
rookgewoonten. 
10. Een onderzoeker die begint aan een promotie-onderzoek is nog lang niet jarig. 



